U.S. patent application number 15/244283 was filed with the patent office on 2016-12-15 for carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases.
The applicant listed for this patent is AbbVie Deutschland GmbH & Co. KG. Invention is credited to Wilfried Braje, Herve Geneste, Wilfried Hornberger, Wilfried Lubisch, Astrid Netz, Thorsten Oost, Liliane Unger, Wolfgang Wernet.
Application Number | 20160362394 15/244283 |
Document ID | / |
Family ID | 40566197 |
Filed Date | 2016-12-15 |
United States Patent
Application |
20160362394 |
Kind Code |
A1 |
Netz; Astrid ; et
al. |
December 15, 2016 |
CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE
TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES
Abstract
The present invention relates to novel carbamate-substituted
oxindole derivatives, pharmaceutical compositions comprising them,
and their use for the treatment of vasopressin-dependent
disorders.
Inventors: |
Netz; Astrid; (Ludwigshafen,
DE) ; Oost; Thorsten; (Biberach an der Riss, DE)
; Geneste; Herve; (Ludwigshafen, DE) ; Braje;
Wilfried; (Ludwigshafen, DE) ; Wernet; Wolfgang;
(Ludwigshafen, DE) ; Unger; Liliane;
(Ludwigshafen, DE) ; Hornberger; Wilfried;
(Ludwigshafen, DE) ; Lubisch; Wilfried;
(Ludwigshafen, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Deutschland GmbH & Co. KG |
Wiesbaden |
|
DE |
|
|
Family ID: |
40566197 |
Appl. No.: |
15/244283 |
Filed: |
August 23, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14252425 |
Apr 14, 2014 |
9422264 |
|
|
15244283 |
|
|
|
|
12746688 |
Nov 29, 2010 |
8703774 |
|
|
PCT/EP2008/066933 |
Dec 5, 2008 |
|
|
|
14252425 |
|
|
|
|
61012251 |
Dec 7, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 7/02 20180101; A61P
25/22 20180101; C07D 401/04 20130101; A61P 11/00 20180101; A61P
25/18 20180101; A61P 3/00 20180101; C07D 401/14 20130101; A61P
13/12 20180101; A61P 3/10 20180101; A61P 1/08 20180101 |
International
Class: |
C07D 401/14 20060101
C07D401/14 |
Claims
1. A compound of the formula I ##STR00004## in which R.sup.1 is
hydrogen, methoxy or ethoxy; R.sup.2 is hydrogen or methoxy;
R.sup.3 is hydrogen, methyl, ethyl, n-propyl or isopropyl; X.sup.1
and X.sup.2 are N or CH, with the proviso that X.sup.1 and X.sup.2
are not simultaneously N; and their pharmaceutically acceptable
salts and prodrugs thereof.
2. A compound as claimed in claim 1, in which R.sup.1 is hydrogen
or methoxy.
3. A compound as claimed in any of the preceding claims, in which
R.sup.3 is hydrogen, methyl or ethyl.
4. A compound as claimed in any of the preceding claims, in which
X.sup.1 is N and X.sup.2 is CH.
5. A compound as claimed in any of claims 1 to 3, in which X.sup.1
is CH and X.sup.2 is N.
6. A compound as claimed in any of claims 1 to 3, in which X.sup.1
is CH and X.sup.2 is CH.
7. A compound as claimed in any of claims 1 to 3 and 5, in which
R.sup.1 is methoxy; R.sup.2 is methoxy; R.sup.3 is methyl or ethyl;
X.sup.1 is CH; and X.sup.2 is N.
8. A compound as claimed in any of claims 1 to 3 and 5, in which
R.sup.1 is methoxy; R.sup.2 is H; R.sup.3 is methyl or ethyl;
X.sup.1 is CH; and X.sup.2 is N.
9. A compound as claimed in any of claims 1 to 3 and 5, in which
R.sup.1 is H; R.sup.2 is methoxy; R.sup.3 is methyl or ethyl;
X.sup.1 is CH; and X.sup.2 is N.
10. A compound as claimed in any of claims 1 to 3 and 5, in which
R.sup.1 is H; R.sup.2 is H; R.sup.3 is methyl or ethyl; X.sup.1 is
CH; and X.sup.2 is N.
11. A compound as claimed in any of claims 1 to 4, in which R.sup.1
is methoxy; R.sup.2 is methoxy; R.sup.3 is methyl or ethyl; X.sup.1
is N; and X.sup.2 is CH.
12. A compound as claimed in any of claims 1 to 4, in which R.sup.1
is methoxy; R.sup.2 is H; R.sup.3 is methyl or ethyl; X.sup.1 is N;
and X.sup.2 is CH.
13. A compound as claimed in any of claims 1 to 4, in which R.sup.1
is H; R.sup.2 is methoxy; R.sup.3 is methyl or ethyl; X.sup.1 is N;
and X.sup.2 is CH.
14. A compound as claimed in any of claims 1 to 4, in which R.sup.1
is H; R.sup.2 is H; R.sup.3 is methyl or ethyl; X.sup.1 is N; and
X.sup.2 is CH.
15. A compound as claimed in any of the preceding claims, which is
the (-) enantiomer in an enantiomeric purity of at least 50%
ee.
16. A compound as claimed in claim 15, where the (-) enantiomer has
an enantiomeric purity of at least 90% ee.
17. A compound as claimed in any of claims 1 to 14, which is the
racemate.
18. A pharmaceutical composition comprising at least one compound
of the formula I as defined in any of the preceding claims and/or
at least one pharmaceutically acceptable salt or prodrug thereof
and at least one pharmaceutically acceptable carrier.
19. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of vasopressin-dependent diseases.
20. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from diabetes, insulin
resistance, nocturnal enuresis, incontinence and diseases in which
impairments of blood clotting occur, and/or for delaying
micturition.
21. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from hypertension,
pulmonary hypertension, heart failure, myocardial infarction,
coronary spasm, unstable angina, PTCA (percutaneous transluminal
coronary angioplasty), ischemias of the heart, impairments of the
renal system, edemas, renal vasospasm, necrosis of the renal
cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome,
impairments of the gastrointestinal tract, gastritic vasospasm,
hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis
occurring during chemotherapy, and travel sickness.
22. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from affective
disorders.
23. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from anxiety disorders and
stress-dependent anxiety disorders.
24. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from memory impairments and
Alzheimer's disease.
25. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from psychoses and
psychotic disorders.
26. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from Cushing's syndrome and
other stress-dependent diseases.
27. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from sleep disorders.
28. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from depressive
disorders.
29. The use as claimed in claim 28 for the treatment and/or
prophylaxis of childhood onset mood disorders.
30. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of vasomotor symptoms and/or thermoregulatory
dysfunctions.
31. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of drug or pharmaceutical dependencies and/or
dependencies mediated by other factors; of stress caused by
withdrawal of one or more factors mediating the dependence; and/or
of stress-induced relapses into drug or pharmaceutical dependencies
and/or dependencies mediated by other factors.
32. The use of compounds of the formula I as defined in any of
claims 1 to 17 or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment
and/or prophylaxis of diseases selected from schizophrenia and
psychosis.
33. A method for treating disorders defined as in any of claims 19
to 32, in which an effective amount of at least one compound of the
formula I as defined in any of claims 1 to 17 or of at least one
pharmaceutically acceptable salt or a prodrug thereof or of a
pharmaceutical composition as claimed in claim 18 is administered
to a patient.
Description
[0001] The present invention relates to novel substituted oxindole
derivatives, pharmaceutical compositions comprising them, and their
use for the treatment of vasopressin-dependent disorders.
[0002] Vasopressin is an endogenous hormone which exerts various
effects on organs and tissues. It is suspected that the vasopressin
system is involved in various pathological states such as, for
example, heart failure and high blood pressure. At present, three
receptors (V1a, V1b or V3 and V2) via which vasopressin mediates
its numerous effects are known. Antagonists of these receptors are
therefore being investigated as possible new therapeutic approaches
for the treatment of diseases (M. Thibonnier, Exp. Opin. Invest.
Drugs 1998, 7(5), 729-740).
[0003] Novel substituted oxindoles having a phenylsulfonyl group in
position 1 are described herein.
1-Phenylsulfonyl-1,3-dihydro-2H-indol-2-ones have previously been
described as ligands of vasopressin receptors. WO 93/15051, WO
95/18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/164668 and
WO 01/98295 also describe derivatives having arylsulfonyl groups in
position 1 of the oxindole structure. These compounds differ from
the compounds of the invention essentially through the substituents
in position 3.
[0004] Thus, WO 93/15051 and WO 98/25901 describe
1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones, in which the oxindole
structure is substituted in position 3 by two alkyl radicals which
may also together form a cycloalkyl radical (spiro linkage), as
ligands of vasopressin receptors. As alternative, the spiro ring
may comprise heteroatoms such as oxygen and nitrogen (optionally
with substituents).
[0005] WO 95/18105 describes
1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones having a nitrogen atom
in position 3 as ligands of vasopressin receptors. In addition,
radicals selected from optionally substituted alkyl, cycloalkyl,
phenyl or benzyl radicals are bonded in position 3.
[0006] WO 03/008407 describes 1-phenylsulfonyloxindoles in which
pyridylpiperazines are linked via an oxycarbonyl group to the
oxindole in position 3.
[0007] WO 2005/030755 describes as example 108 the
2-methoxypyridin-3-yl carbamate compound
5-cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxo-2-
,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate (according to
IUPAC nomenclature:
5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-2-oxo-
-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazin-1-carboxylate).
[0008] WO 2006/005609 describes the 2-ethoxyphenyl carbamate
compounds
1-(2,4-dimethoxy-1-benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3--
dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate (example 63) and
5-cyano-1-(2,4-dimethoxybenzenesulfonyl)-3-(2-ethoxyphenyl)-2-oxo-2,3-dih-
ydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate dihydrochloride
(example 172).
[0009] Besides the binding affinity for the vasopressin V1b
receptor, further properties may be advantageous for the treatment
and/or prophylaxis of vasopressin-dependent disorders, such as, for
example:
1.) a selectivity for the vasopressin V1b receptor compared with
the vasopressin V1a receptor, i.e. the quotient of the binding
affinity for the V1a receptor (Ki(V1a) (determined in the unit
"nanomolar (nM)") and the binding affinity for the V1b receptor
(Ki(V1b)) (determined in the unit "nanomolar (nM)"). A larger
quotient Ki(V1a)/Ki(V1b) means a greater V1b selectivity; 2.) a
selectivity for the vasopressin V1b receptor compared with the
vasopressin V2 receptor, i.e. the quotient of the binding affinity
for the V2 receptor (Ki(V2) (determined in the unit "nanomolar
(nM)") and the binding affinity for the V1b receptor (Ki(V1b))
(determined in the unit "nanomolar (nM)"). A larger quotient
Ki(V2)/Ki(V1b) means a greater V1b selectivity; 3.) a selectivity
for the vasopressin V1b receptor compared with the oxytocin OT
receptor, i.e. the quotient of the binding affinity for the OT
receptor (Ki(OT) (determined in the unit "nanomolar (nM)") and the
binding affinity for the V1b receptor (Ki(V1b)) (determined in the
unit "nanomolar (nM)"). A larger quotient Ki(OT)/Ki(V1b) means a
greater V1b selectivity. 4.) the metabolic stability, for example
determined from the half-lives, measured in vitro, in liver
microsomes from various species (e.g. rat or human); 5.) no or only
low inhibition of cytochrome P450 (CYP) enzymes: cytochrome P450
(CYP) is the name for a superfamily of heme proteins having
enzymatic activity (oxidase). They are also particularly important
for the degradation (metabolism) of foreign substances such as
drugs or xenobiotics in mammalian organisms. The principal
representatives of the types and subtypes of CYP in the human body
are: CYP 1A2, CYP 2C9, CYP 2D6 and CYP 3A4. If CYP 3A4 inhibitors
(e.g. grapefruit juice, cimetidine, erythromycin) are used at the
same time as medicinal substances which are degraded by this enzyme
system and thus compete for the same binding site on the enzyme,
the degradation thereof may be slowed down and thus effects and
side effects of the administered medicinal substance may be
undesirably enhanced; 6.) a suitable solubility in water (in
mg/ml); 7.) suitable pharmacokinetics (time course of the
concentration of the compound of the invention in plasma or in
tissue, for example brain). The pharmacokinetics can be described
by the following parameters: half-life, volume of distribution,
plasma clearance, AUC (area under the curve, area under the
concentration-time curve), oral bioavailability, the so-called
brain-plasma ratio; 8.) a suitable portion of the active substance
is bound to plasma proteins (drug-plasma protein binding (PPB)
value); 9.) no or only low blockade of the hERG channel: compounds
which block the hERG channel may cause a prolongation of the QT
interval and thus lead to serious disturbances of cardiac rhythm
(for example so-called "torsade de pointes"). The potential of
compounds to block the hERG channel can be determined by means of
the displacement assay with radiolabelled dofetilide which is
described in the literature (G. J. Diaz et al., Journal of
Pharmacological and Toxicological Methods, 50 (2004), 187-199). A
smaller IC50 in this dofetilide assay means a greater probability
of potent hERG blockade. In addition, the blockade of the hERG
channel can be measured by electrophysiological experiments on
cells which have been transfected with the hERG channel, by
so-called whole-cell patch clamping (G. J. Diaz et al., Journal of
Pharmacological and Toxicological Methods, 50 (2004), 187-199).
[0010] It was therefore an object of the present invention to
provide compounds for the treatment or prophylaxis of various
vasopressin-dependent diseases. The compounds were intended to have
a high activity and selectivity, especially a high affinity and
selectivity vis-a-vis the vasopressin V1b receptor. In addition,
the substance of the invention was intended to have one or more of
the aforementioned advantages 1.) to 9.).
[0011] The object is achieved by compounds of the formula I
##STR00001##
in which [0012] R.sup.1 is hydrogen, methoxy or ethoxy; [0013]
R.sup.2 is hydrogen or methoxy; [0014] R.sup.3 is hydrogen, methyl,
ethyl, n-propyl or isopropyl; [0015] X.sup.1 and X.sup.2 are N or
CH, with the proviso that X.sup.1 and X.sup.2 are not
simultaneously N; and by their pharmaceutically acceptable salts
and prodrugs thereof.
[0016] Accordingly, the present invention relates to compounds of
the formula I (also "compounds I" hereinafter) and the
pharmaceutically acceptable salts of the compounds I and the
prodrugs of the compounds I.
[0017] The pharmaceutically acceptable salts of compounds of the
formula I, which are also referred to as physiologically tolerated
salts, are ordinarily obtainable by reacting the free base of the
compounds I of the invention (i.e. of the compounds I according to
structural formula I) with suitable acids. Examples of suitable
acids are listed in "Fortschritte der Arzneimittelforschung", 1966,
Birkhauser Verlag, vol. 10, pp. 224-285. These include for example
hydrochloric acid, citric acid, tartaric acid, lactic acid,
phosphoric acid, methanesulfonic acid, acetic acid, formic acid,
maleic acid and fumaric acid.
[0018] The term "prodrugs" means compounds which are metabolized in
vivo to the compounds I of the invention. Typical examples of
prodrugs are described in C. G. Wermeth (editor): The Practice of
Medicinal Chemistry, Academic Press, San Diego, 1996, pages
671-715. These include for example phosphates, carbamates, amino
acids, esters, amides, peptides, ureas and the like. Suitable
prodrugs in the present case may be for example compounds I in
which the outer nitrogen atom of the outer piperidine/piperazine
ring forms an amide/peptide linkage by this nitrogen atom being
substituted by a C.sub.1-C.sub.4-alkylcarbonyl group, e.g. by
acetyl, propionyl, n-propylcarbonyl, isopropylcarbonyl,
n-butylcarbonyl or tert-butylcarbonyl (pivaloyl), by benzoyl, or by
an amino acid residue linked via CO, e.g. glycine, alanine, serine,
phenylalanine and the like linked via CO, in the position of the
radical R.sup.3. Further suitable prodrugs are
alkylcarbonyloxyalkyl carbamates in which the outer nitrogen atom
of the outer piperidine/piperazine ring has in the position of the
radical R.sup.3 a group of the formula
--C(.dbd.O)--O--CHR.sup.a--O--C(.dbd.O)--R.sup.b in which R.sup.a
and R.sup.b are independently of one another C.sub.1-C.sub.4-alkyl.
Such carbamates are described for example in J. Alexander, R.
Cargill, S. R. Michelson, H. Schwam, J. Medicinal Chem. 1988,
31(2), 318-322. These groups can then be eliminated under metabolic
conditions and result in compounds I in which R.sup.3 is H.
[0019] C.sub.1-C.sub.4-Alkyl is in the context of the present
invention a linear or branched alkyl radical having 1 to 4 carbon
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl,
sec-butyl, isobutyl or tert-butyl.
[0020] C.sub.1-C.sub.3-Alkoxy is in the context of the present
invention a linear or branched alkyl radical linked via an oxygen
atom and having 1 to 3 carbon atoms. Examples are methoxy, ethoxy,
n-propoxy and isopropoxy.
[0021] The compounds of the invention of the formula I, their
pharmacologically acceptable salts and their prodrugs may also be
present in the form of solvates or hydrates. Solvates mean in the
context of the present invention crystalline forms of the compounds
I or of their pharmaceutically acceptable salts or prodrugs thereof
which comprise solvent molecules incorporated in the crystal
lattice. The solvent molecules are preferably incorporated in
stoichiometric ratios. Hydrates are a specific form of solvates;
the solvent in this case is water.
[0022] The statements made hereinafter concerning suitable and
preferred features of the invention, especially concerning the
variables R.sup.1, R.sup.2, R.sup.3, X.sup.1 and X.sup.2 in the
compound I, but also concerning the features of the process of the
invention and of the use according to the invention apply both
taken on their own and preferably in any possible combination with
one another.
[0023] The compounds I are preferably provided in the form of the
free base (i.e. according to structural formula I) or in the form
of their acid addition salts.
[0024] In a preferred embodiment, R.sup.1 is hydrogen or
methoxy.
[0025] In a particularly preferred embodiment, R.sup.1 and R.sup.2
are both H.
[0026] In an alternatively preferred embodiment, R.sup.1 is methoxy
and R.sup.2 is H.
[0027] In an alternatively particularly preferred embodiment,
R.sup.1 is H and R.sup.2 is methoxy.
[0028] In an alternatively particularly preferred embodiment,
R.sup.1 and R.sup.2 are both methoxy.
[0029] In a further preferred embodiment, R.sup.3 is hydrogen,
methyl or ethyl.
[0030] In a further preferred embodiment, one of the variables
X.sup.1, X.sup.2 is N and the other is CH.
[0031] In a particularly preferred embodiment in this connection,
X.sup.1 is N and X.sup.2 is CH.
[0032] In an alternatively particularly preferred embodiment,
X.sup.1 is CH and X.sup.2 is N.
[0033] The invention preferably relates to compounds of the formula
I in which [0034] R.sup.1 is hydrogen or methoxy; [0035] R.sup.2 is
hydrogen or methoxy; [0036] R.sup.3 is hydrogen, methyl, ethyl,
n-propyl or isopropyl, preferably hydrogen, methyl or ethyl; [0037]
X.sup.1 is N or CH; [0038] X.sup.2 is N or CH; where X.sup.1 and
X.sup.2 are not simultaneously N; and the pharmaceutically
acceptable salts and prodrugs thereof.
[0039] In a particular embodiment, one of the variables X.sup.1 or
X.sup.2 is N and the other is CH.
[0040] The invention particularly preferably relates to compounds
of the formula I in which [0041] R.sup.1 is hydrogen or methoxy;
[0042] R.sup.2 is hydrogen or methoxy; [0043] R.sup.3 is hydrogen,
methyl or ethyl; [0044] X.sup.1 is N; [0045] X.sup.2 is CH; and the
pharmaceutically acceptable salts and prodrugs thereof.
[0046] The invention alternatively particularly preferably relates
to compounds of the formula I in which [0047] R.sup.1 is hydrogen
or methoxy; [0048] R.sup.2 is hydrogen or methoxy; [0049] R.sup.3
is hydrogen, methyl or ethyl; [0050] X.sup.1 is CH; [0051] X.sup.2
is N; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0052] The invention further particularly preferably relates to
compounds of the formula I in which [0053] R.sup.1 is hydrogen or
methoxy; [0054] R.sup.2 is hydrogen or methoxy; [0055] R.sup.3 is
hydrogen, methyl or ethyl; [0056] X.sup.1 is CH; [0057] X.sup.2 is
CH; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0058] The invention particularly relates to compounds of the
formula I in which [0059] R.sup.1 is methoxy; [0060] R.sup.2 is
methoxy; [0061] R.sup.3 is hydrogen, methyl or ethyl, preferably
methyl or ethyl; [0062] X.sup.1 is CH; [0063] X.sup.2 is N; and the
pharmaceutically acceptable salts and prodrugs thereof.
[0064] The invention furthermore particularly relates to compounds
of the formula I in which [0065] R.sup.1 is hydrogen; [0066]
R.sup.2 is methoxy; [0067] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0068] X.sup.1 is CH; [0069] X.sup.2 is
N; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0070] The invention furthermore particularly relates to compounds
of the formula I in which [0071] R.sup.1 is methoxy; [0072] R.sup.2
is hydrogen; [0073] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0074] X.sup.1 is CH; [0075] X.sup.2 is
N; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0076] The invention furthermore preferably relates to compounds of
the formula I in which [0077] R.sup.1 is hydrogen; [0078] R.sup.2
is hydrogen; [0079] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0080] X.sup.1 is CH; [0081] X.sup.2 is
N; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0082] The invention furthermore particularly relates to compounds
of the formula I in which [0083] R.sup.1 is methoxy; [0084] R.sup.2
is methoxy; [0085] R.sup.3 is hydrogen, methyl or ethyl, preferably
methyl or ethyl; [0086] X.sup.1 is N; [0087] X.sup.2 is CH; and the
pharmaceutically acceptable salts and prodrugs thereof.
[0088] The invention furthermore particularly relates to compounds
of the formula I in which [0089] R.sup.1 is hydrogen; [0090]
R.sup.2 is methoxy; [0091] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0092] X.sup.1 is N; [0093] X.sup.2 is
CH; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0094] The invention furthermore particularly relates to compounds
of the formula I in which [0095] R.sup.1 is methoxy; [0096] R.sup.2
is hydrogen; [0097] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0098] X.sup.1 is N; [0099] X.sup.2 is
CH; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0100] The invention furthermore particularly relates to compounds
of the formula I in which [0101] R.sup.1 is hydrogen; [0102]
R.sup.2 is hydrogen; [0103] R.sup.3 is hydrogen, methyl or ethyl,
preferably methyl or ethyl; [0104] X.sup.1 is N; [0105] X.sup.2 is
CH; and the pharmaceutically acceptable salts and prodrugs
thereof.
[0106] Examples of preferred embodiment of the present invention
are compounds of the formula I and the pharmaceutically acceptable
salts and prodrugs thereof, in which the radicals X.sup.1, X.sup.2,
R.sup.1, R.sup.2 and R.sup.3 assume in each case the meanings
mentioned in each line in the following table 1.
TABLE-US-00001 TABLE 1 Example No. X.sup.1 X.sup.2 R.sup.1 R.sup.2
R.sup.3 1 N CH Methoxy Methoxy Methyl 2 N CH Methoxy H Methyl 3 N
CH Ethoxy H Methyl 4 N CH H H Methyl 5 N CH H Methoxy Methyl 6 N CH
Ethoxy Methoxy Methyl 7 N CH Methoxy Methoxy Ethyl 8 N CH Methoxy H
Ethyl 9 N CH Ethoxy H Ethyl 10 N CH H H Ethyl 11 N CH H Methoxy
Ethyl 12 N CH Ethoxy Methoxy Ethyl 13 N CH Methoxy Methoxy n-Propyl
14 N CH Methoxy H n-Propyl 15 N CH Ethoxy H n-Propyl 16 N CH H H
n-Propyl 17 N CH H Methoxy n-Propyl 18 N CH Ethoxy Methoxy n-Propyl
19 N CH Methoxy Methoxy Isopropyl 20 N CH Methoxy H Isopropyl 21 N
CH Ethoxy H Isopropyl 22 N CH H H Isopropyl 23 N CH H Methoxy
Isopropyl 24 N CH Ethoxy Methoxy Isopropyl 25 N CH Methoxy Methoxy
H 26 N CH Methoxy H H 27 N CH Ethoxy H H 28 N CH H H H 29 N CH H
Methoxy H 30 N CH Ethoxy Methoxy H 31 CH N Methoxy Methoxy Methyl
32 CH N Methoxy H Methyl 33 CH N Ethoxy H Methyl 34 CH N H H Methyl
35 CH N H Methoxy Methyl 36 CH N Ethoxy Methoxy Methyl 37 CH N
Methoxy Methoxy Ethyl 38 CH N Methoxy H Ethyl 39 CH N Ethoxy H
Ethyl 40 CH N H H Ethyl 41 CH N H Methoxy Ethyl 42 CH N Ethoxy
Methoxy Ethyl 43 CH N Methoxy Methoxy n-Propyl 44 CH N Methoxy H
n-Propyl 45 CH N Ethoxy H n-Propyl 46 CH N H H n-Propyl 47 CH N H
Methoxy n-Propyl 48 CH N Ethoxy Methoxy n-Propyl 49 CH N Methoxy
Methoxy Isopropyl 50 CH N Methoxy H Isopropyl 51 CH N Ethoxy H
Isopropyl 52 CH N H H Isopropyl 53 CH N H Methoxy Isopropyl 54 CH N
Ethoxy Methoxy Isopropyl 55 CH N Methoxy Methoxy H 56 CH N Methoxy
H H 57 CH N Ethoxy H H 58 CH N H H H 59 CH N H Methoxy H 60 CH N
Ethoxy Methoxy H 61 CH CH Methoxy Methoxy Methyl 62 CH CH Methoxy H
Methyl 63 CH CH Ethoxy H Methyl 64 CH CH H H Methyl 65 CH CH H
Methoxy Methyl 66 CH CH Ethoxy Methoxy Methyl 67 CH CH Methoxy
Methoxy Ethyl 68 CH CH Methoxy H Ethyl 69 CH CH Ethoxy H Ethyl 70
CH CH H H Ethyl 71 CH CH H Methoxy Ethyl 72 CH CH Ethoxy Methoxy
Ethyl 73 CH CH Methoxy Methoxy n-Propyl 74 CH CH Methoxy H n-Propyl
75 CH CH Ethoxy H n-Propyl 76 CH CH H H n-Propyl 77 CH CH H Methoxy
n-Propyl 78 CH CH Ethoxy Methoxy n-Propyl 79 CH CH Methoxy Methoxy
Isopropyl 80 CH CH Methoxy H Isopropyl 81 CH CH Ethoxy H Isopropyl
82 CH CH H H Isopropyl 83 CH CH H Methoxy Isopropyl 84 CH CH Ethoxy
Methoxy Isopropyl 85 CH CH Methoxy Methoxy H 86 CH CH Methoxy H H
87 CH CH Ethoxy H H 88 CH CH H H H 89 CH CH H Methoxy H 90 CH CH
Ethoxy Methoxy H
[0107] The compounds I of the invention have a center of chirality
in position 3 of the 2-oxindole ring. The compounds of the
invention may therefore be in the form of a 1:1 mixture of
enantiomers (racemate) or of a nonracemic mixture of enantiomers in
which one of the two enantiomers, either the enantiomer which
rotates the plane of vibration of linearly polarized light to the
left (i.e. minus rotation) (hereinafter (-) enantiomer) or the
enantiomer which rotates the plane of vibration of linearly
polarized light to the right (i.e. plus rotation) (hereinafter (+)
enantiomer), is enriched, or of substantially enantiopure
compounds, that is to say of substantially enantiopure (-)
enantiomer or (+) enantiomer. Since the compounds of the invention
have a single center of asymmetry and no axis/plane of chirality, a
nonracemic mixture can also be defined as a mixture of enantiomers
in which either the R or the S enantiomer predominates.
Substantially enantiopure compounds can accordingly also be defined
as substantially enantiopure R enantiomer or substantially
enantiopure S enantiomer.
[0108] "Substantially enantiopure compounds" means in the context
of the present invention those compounds having an enantiomeric
excess (ee; % ee=(R-S)/(R+S).times.100 or (S-R)/(S+R).times.100) of
at least 80% ee, preferably at least 85% ee, more preferably at
least 90% ee, even more preferably at least 95% ee and in
particular at least 98% ee.
[0109] In one embodiment of the invention, the compounds of the
invention are in the form of substantially enantiopure compounds.
Particularly preferred compounds have an enantiomeric excess of at
least 85% ee, more preferably of at least 90% ee, even more
preferably of at least 95% ee and in particular of at least 98%
ee.
[0110] The invention thus relates both to the pure enantiomers and
to mixtures thereof, e.g. mixtures in which one enantiomer is
present in enriched form, but also to the racemates. The invention
also relates to the pharmaceutically acceptable salts and the
prodrugs of the pure enantiomers of compounds I, and the mixtures
of enantiomers in the form of the pharmaceutically acceptable salts
and prodrugs of compounds I.
[0111] Preferred embodiments of the invention are compounds of the
formula I as detailed above which are characterized in that they
are in optically active form, and the enantiomer of the relevant
compound of the formula I is the one which rotates the plane of
vibration of polarized light to the left (i.e. minus rotation), in
the form of a free base, or a pharmaceutically acceptable salt or a
prodrug thereof. The enantiomers with levorotation or minus
rotation of the compounds I are also referred to hereinafter as (-)
enantiomers.
[0112] The statements made in the context of the present invention
concerning the direction of rotation of polarized light relate
preferably to the signs [(+) or (-)] as determined in chloroform as
solvent or in chloroform-containing solvent mixtures, in particular
in chloroform.
[0113] Preferred embodiments of the invention are those compounds
of the formula I as detailed above which are characterized in that
they are in optically active form, with the absolute configuration
at the chiral C-3 ring carbon atom of the oxindole structure
corresponding to the absolute configuration at C-3 of the (-)
enantiomer of the compound
5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo--
2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate (=compound of
example 1) in the form of the free base. This configuration is also
referred to hereinafter as the "preferred configuration".
[0114] Particular preference is given to compounds of the general
formula I, pharmaceutically acceptable salts and their prodrugs as
detailed above in which the corresponding (-) enantiomer is present
in an optical purity (enantiomeric excess, ee) of more than 50% ee,
particularly preferably of at least 80% ee, more preferably of at
least 90% ee and even more preferably of at least 95% ee and in
particular of at least 98% ee.
[0115] Particular preference is alternatively given to compounds of
the general formula I, their pharmaceutically acceptable salts and
their prodrugs in which the enantiomer displaying the preferred
absolute configuration at the C-3 ring carbon atom is present in
with an optical purity (enantiomeric excess, ee) of more than 50%
ee, preferably of at least 80% ee, more preferably of at least 90%
ee, even more preferably of at least 95% ee and in particular of at
least 98% ee.
[0116] Likewise preferred embodiments of the invention are
compounds of the general formula I as detailed above which are
characterized in that they are in optically inactive form, i.e. in
the form of the racemate, or in the form of a pharmaceutically
acceptable salt or of a prodrug of the racemate.
[0117] Examples of particularly preferred compounds I are the
compounds listed in following table 2 with the example numbers 1 to
90B, and the pharmaceutically acceptable salts and prodrugs
thereof. In this connection, examples 1 to 90 correspond to the
racemate of the respective compounds, the examples with an appended
letter "A" (1A, 2A, . . . to 90A) correspond to the dextrorotatory
(+) enantiomer and the examples with an appended letter "B" (1B,
2B, . . . to 90B) correspond to the levorotatory (-) enantiomer of
the respective compound 1 to 90. The naming of the compounds
corresponds to the naming generated by the ACD-Labs version 8.00
release product version 8.05.
TABLE-US-00002 TABLE 2 Example No. X.sup.1 X.sup.2 R.sup.1 R.sup.2
R.sup.3 IUPAC Name 1 N CH Methoxy Methoxy Methyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 1A N CH Methoxy
Methoxy Methyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 1B N CH Methoxy
Methoxy Methyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 2 N CH Methoxy H
Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 2A N CH Methoxy
H Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 2B N CH Methoxy
H Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 3 N CH Ethoxy H
Methyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 3A N CH Ethoxy H
Methyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 3B N CH Ethoxy H
Methyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 4 N CH H H
Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 4A N CH H H
Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
4B N CH H H Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
5 N CH H Methoxy Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 5A N CH H
Methoxy Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 5B N CH H
Methoxy Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate 6 N CH Ethoxy
Methoxy Methyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1- carboxylate 6A N CH Ethoxy
Methoxy Methyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1- carboxylate 6B N CH Ethoxy
Methoxy Methyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1- carboxylate 7 N CH Methoxy
Methoxy Ethyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 7A N CH Methoxy
Methoxy Ethyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 7B N CH Methoxy
Methoxy Ethyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 8 N CH Methoxy H
Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 8A N CH Methoxy H
Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 8B N CH Methoxy H
Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 9 N CH Ethoxy H
Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 9A N CH Ethoxy H
Ethyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 9B N CH Ethoxy H
Ethyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 10 N CH H H Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 10A N CH H H
Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate
10B N CH H H Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate
11 N CH H Methoxy Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 11A N CH H
Methoxy Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 11B N CH H
Methoxy Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 12 N CH Ethoxy
Methoxy Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 12A N CH Ethoxy
Methoxy Ethyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 12B N CH Ethoxy
Methoxy Ethyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate 13 N CH Methoxy
Methoxy n-Propyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 13A N CH Methoxy
Methoxy n-Propyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 13B N CH Methoxy
Methoxy n-Propyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 14 N CH Methoxy
H n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 14A N CH Methoxy
H n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 14B N CH Methoxy
H n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 15 N CH Ethoxy H
n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 15A N CH Ethoxy
H n-Propyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 15B N CH Ethoxy
H n-Propyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 16 N CH H H
n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 16A N CH H H
n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate
16B N CH H H n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate
17 N CH H Methoxy n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 17A N CH H
Methoxy n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 17B N CH H
Methoxy n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1-carboxylate 18 N CH Ethoxy
Methoxy n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1- carboxylate 18A N CH Ethoxy
Methoxy n-Propyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1- carboxylate 18B N CH Ethoxy
Methoxy n-Propyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-propylpiperidin-4-yl)piperazine-1- carboxylate 19 N CH Methoxy
Methoxy Isopropyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 19A N CH
Methoxy Methoxy Isopropyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 19B N CH
Methoxy Methoxy Isopropyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 20 N CH
Methoxy H Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 20A N CH
Methoxy H Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 20B N CH
Methoxy H Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 21 N CH
Ethoxy H Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 21A N CH
Ethoxy H Isopropyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 21B N CH
Ethoxy H Isopropyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 22 N CH H H
Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 22A N CH H H
Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 22B N CH H H
Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 23 N CH H
Methoxy Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 23A N CH H
Methoxy Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 23B N CH H
Methoxy Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxylate 24 N CH
Ethoxy Methoxy Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1- carboxylate 24A N CH
Ethoxy Methoxy Isopropyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1- carboxylate 24B N CH
Ethoxy Methoxy Isopropyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(1-isopropylpiperidin-4-yl)piperazine-1- carboxylate 25 N CH
Methoxy Methoxy H
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 25A N CH Methoxy Methoxy H
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 25B N CH Methoxy Methoxy H
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 26 N CH Methoxy H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 26A N CH Methoxy H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
26B N CH Methoxy H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
27 N CH Ethoxy H H
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 27A N CH Ethoxy H H
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
27B N CH Ethoxy H H
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
28 N CH H H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate 28A N
CH H H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate 28B N CH H
H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate 29 N CH H
Methoxy H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 29A N CH H Methoxy H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
29B N CH H Methoxy H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
30 N CH Ethoxy Methoxy H
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 30A N CH Ethoxy Methoxy H
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 30B N CH Ethoxy Methoxy H
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 31 CH N Methoxy Methoxy
Methyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 31A CH N Methoxy Methoxy
Methyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 31B CH N Methoxy Methoxy
Methyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate 32 CH N Methoxy H Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 32A CH N Methoxy
H Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 32B CH N Methoxy
H Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 33 CH N Ethoxy H
Methyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 33A CH N Ethoxy
H Methyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 33B CH N Ethoxy
H Methyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 34 CH N H H
Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 34A CH N H H
Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
34B CH N H H Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
35 CH N H Methoxy Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 35A CH N H
Methoxy Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 35B CH N H
Methoxy Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 36 CH N Ethoxy
Methoxy Methyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1- carboxylate 36A CH N Ethoxy
Methoxy Methyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1- carboxylate 36B CH N Ethoxy
Methoxy Methyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1- carboxylate 37 CH N Methoxy
Methoxy Ethyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 37A CH N Methoxy
Methoxy Ethyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 37B CH N Methoxy
Methoxy Ethyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 38 CH N Methoxy H
Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 38A CH N Methoxy
H Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 38B CH N Methoxy
H Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 39 CH N Ethoxy H
Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 39A CH N Ethoxy H
Ethyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 39B CH N Ethoxy H
Ethyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 40 CH N H H Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 40A CH N H H
Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
40B CH N H H Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
41 CH N H Methoxy Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 41A CH N H
Methoxy Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 41B CH N H
Methoxy Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 42 CH N Ethoxy
Methoxy Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 42A CH N Ethoxy
Methoxy Ethyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 42B CH N Ethoxy
Methoxy Ethyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate 43 CH N Methoxy
Methoxy n-Propyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 43A CH N Methoxy
Methoxy n-Propyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 43B CH N Methoxy
Methoxy n-Propyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 44 CH N Methoxy
H n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 44A CH N Methoxy
H n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 44B CH N Methoxy
H n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 45 CH N Ethoxy H
n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 45A CH N Ethoxy
H n-Propyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 45B CH N Ethoxy
H n-Propyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 46 CH N H H
n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 46A CH N H H
n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate
46B CH N H H n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate
47 CH N H Methoxy n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 47A CH N H
Methoxy n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 47B CH N H
Methoxy n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1-carboxylate 48 CH N Ethoxy
Methoxy n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1- carboxylate 48A CH N Ethoxy
Methoxy n-Propyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1- carboxylate 48B CH N Ethoxy
Methoxy n-Propyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-propylpiperazin-1-yl)piperidine-1- carboxylate 49 CH N Methoxy
Methoxy Isopropyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 49A CH N
Methoxy Methoxy Isopropyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 49B CH N
Methoxy Methoxy Isopropyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 50 CH N
Methoxy H Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 50A CH N
Methoxy H Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 50B CH N
Methoxy H Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 51 CH N
Ethoxy H Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 51A CH N
Ethoxy H Isopropyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 51B CH N
Ethoxy H Isopropyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 52 CH N H H
Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H-
indol-3-yl 4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate
52A CH N H H Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 52B CH N H H
Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 53 CH N H
Methoxy Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 53A CH N H
Methoxy Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 53B CH N H
Methoxy Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxylate 54 CH N
Ethoxy Methoxy Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1- carboxylate 54A CH N
Ethoxy Methoxy Isopropyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1- carboxylate 54B CH N
Ethoxy Methoxy Isopropyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-(4-isopropylpiperazin-1-yl)piperidine-1- carboxylate 55 CH N
Methoxy Methoxy H
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 55A CH N Methoxy Methoxy H
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 55B CH N Methoxy Methoxy H
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 56 CH N Methoxy H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 56A CH N Methoxy H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
56B CH N Methoxy H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
57 CH N Ethoxy H H
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 57A CH N Ethoxy H H
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
57B CH N Ethoxy H H
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
58 CH N H H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate 58A CH
N H H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate 58B CH N H
H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate 59 CH N H
Methoxy H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 59A CH N H Methoxy H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
59B CH N H Methoxy H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
60 CH N Ethoxy Methoxy H
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 60A CH N Ethoxy Methoxy H
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 60B CH N Ethoxy Methoxy H
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4-piperazin-1-ylpiperidine-1-carboxylate 61 CH CH Methoxy Methoxy
Methyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 61A CH CH Methoxy Methoxy
Methyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 61B CH CH Methoxy Methoxy
Methyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 62 CH CH Methoxy H Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 62A CH CH Methoxy H
Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 62B CH CH Methoxy H
Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 63 CH CH Ethoxy H Methyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 63A CH CH Ethoxy H Methyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-methyl-4,4'-bipiperidine-1-carboxylate
63B CH CH Ethoxy H Methyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-methyl-4,4'-bipiperidine-1-carboxylate
64 CH CH H H Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 1'-methyl-4,4'-bipiperidine-1-carboxylate 64A CH
CH H H Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-methyl-4,4'-bipiperidine-1-carboxylate 64B CH CH
H H Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-methyl-4,4'-bipiperidine-1-carboxylate 65 CH CH
H Methoxy Methyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 65A CH CH H Methoxy
Methyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 65B CH CH H Methoxy
Methyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 66 CH CH Ethoxy Methoxy
Methyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 66A CH CH Ethoxy Methoxy
Methyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 66B CH CH Ethoxy Methoxy
Methyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-methyl-4,4'-bipiperidine-1-carboxylate 67 CH CH Methoxy Methoxy
Ethyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 67A CH CH Methoxy Methoxy
Ethyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 67B CH CH Methoxy Methoxy
Ethyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 68 CH CH Methoxy H Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 68A CH CH Methoxy H Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate
68B CH CH Methoxy H Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate
69 CH CH Ethoxy H Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 69A CH CH Ethoxy H Ethyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate
69B CH CH Ethoxy H Ethyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate
70 CH CH H H Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate 70A CH
CH H H Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate 70B CH CH
H H Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate 71 CH CH H
Methoxy Ethyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 71A CH CH H Methoxy Ethyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate
71B CH CH H Methoxy Ethyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3-
dihydro-1H-indol-3-yl 1'-ethyl-4,4'-bipiperidine-1-carboxylate 72
CH CH Ethoxy Methoxy Ethyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 72A CH CH Ethoxy Methoxy
Ethyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 72B CH CH Ethoxy Methoxy
Ethyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-ethyl-4,4'-bipiperidine-1-carboxylate 73 CH CH Methoxy Methoxy
n-Propyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 73A CH CH Methoxy Methoxy
n-Propyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 73B CH CH Methoxy Methoxy
n-Propyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 74 CH CH Methoxy H
n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 74A CH CH Methoxy H
n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 74B CH CH Methoxy H
n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 75 CH CH Ethoxy H
n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 75A CH CH Ethoxy H
n-Propyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-propyl-4,4'-bipiperidine-1-carboxylate
75B CH CH Ethoxy H n-Propyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 1'-propyl-4,4'-bipiperidine-1-carboxylate
76 CH CH H H n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 1'-propyl-4,4'-bipiperidine-1-carboxylate 76A CH
CH H H n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-propyl-4,4'-bipiperidine-1-carboxylate 76B CH CH
H H n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-propyl-4,4'-bipiperidine-1-carboxylate 77 CH CH
H Methoxy n-Propyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 77A CH CH H Methoxy
n-Propyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 77B CH CH H Methoxy
n-Propyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 78 CH CH Ethoxy Methoxy
n-Propyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 78A CH CH Ethoxy Methoxy
n-Propyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 78B CH CH Ethoxy Methoxy
n-Propyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-propyl-4,4'-bipiperidine-1-carboxylate 79 CH CH Methoxy Methoxy
Isopropyl
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 79A CH CH Methoxy
Methoxy Isopropyl
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 79B CH CH Methoxy
Methoxy Isopropyl
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 80 CH CH Methoxy H
Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 80A CH CH Methoxy H
Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 80B CH CH Methoxy H
Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 81 CH CH Ethoxy H
Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 81A CH CH Ethoxy H
Isopropyl
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 81B CH CH Ethoxy H
Isopropyl
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 82 CH CH H H Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 1'-isopropyl-4,4'-bipiperidine-1-carboxylate 82A
CH CH H H Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-isopropyl-4,4'-bipiperidine-1-carboxylate 82B CH
CH H H Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 1'-isopropyl-4,4'-bipiperidine-1-carboxylate 83 CH
CH H Methoxy Isopropyl
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 83A CH CH H Methoxy
Isopropyl
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 83B CH CH H Methoxy
Isopropyl
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 84 CH CH Ethoxy
Methoxy Isopropyl
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 84A CH CH Ethoxy
Methoxy Isopropyl
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 84B CH CH Ethoxy
Methoxy Isopropyl
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
1'-isopropyl-4,4'-bipiperidine-1-carboxylate 85 CH CH Methoxy
Methoxy H
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo- 2,3-dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate
85A CH CH Methoxy Methoxy H
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 85B
CH CH Methoxy Methoxy H
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo- 2,3-dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 86
CH CH Methoxy H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 86A
CH CH Methoxy H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 86B CH
CH Methoxy H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 87 CH CH
Ethoxy H H
(.+-.)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-ox-
o-2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 87A CH
CH Ethoxy H H
(+)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 87B CH CH
Ethoxy H H
(-)-5-Cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 88 CH CH
H H H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihy-
dro-1H- indol-3-yl 4,4'-bipiperidine-1-carboxylate 88A CH CH H H H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4,4'-bipiperidine-1-carboxylate 88B CH CH H H H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H- indol-3-yl 4,4'-bipiperidine-1-carboxylate 89 CH CH H Methoxy
H
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-o-
xo-2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 89A
CH CH H Methoxy H
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 89B CH
CH H Methoxy H
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-oxo--
2,3- dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate 90 CH CH
Ethoxy Methoxy H
(.+-.)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin--
3-yl)-2- oxo-2,3-dihydro-1H-indol-3-yl
4,4'-bipiperidine-1-carboxylate 90A CH CH Ethoxy Methoxy H
(+)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl 4,4'-bipiperidine-1-carboxylate
90B CH CH Ethoxy Methoxy H
(-)-5-Cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-y-
l)-2- oxo-2,3-dihydro-1H-indol-3-yl
4,4'-bipiperidine-1-carboxylate
[0118] Among these, particular preference is given to the racemates
(i.e. compounds 1, 2, . . . 90) and their physiologically tolerated
salts, and their prodrugs. Also particularly preferred are the (-)
enantiomers (i.e. compounds 1B, 2B, . . . 90B) and their
physiologically tolerated salts, and their prodrugs. The
aforementioned compounds are provided in particular in the form of
their free base or in the form of their acid addition salts.
[0119] Examples of synthetic routes for preparing the oxindole
derivatives of the invention are described below.
[0120] The oxindoles of the invention can be prepared in various
ways, and the preparation is outlined in synthesis schemes 1 and 2.
The variables in these synthetic schemes have the same meanings as
in formula I.
[0121] The 3-hydroxy-1,3-dihydroindol-2-ones IV can be obtained by
addition of metallated heterocycles III onto the 3-keto group of
the isatins II. The metallated heterocycles, such as, for example,
the corresponding Grignard (Mg) or organyllithium compound, can be
obtained in any conventional way from halogen or hydrocarbon
compounds. Examples of methods are present in Houben-Weyl, Methoden
der Organischen Chemie, vol. 13, 1-2, chapter on Mg and Li
compounds. The isatins II are either commercially available or can
be prepared in analogy to methods described in the literature
(Advances in Heterocyclic Chemistry, A. R. Katritzky and A. J.
Boulton, Academic Press, New York, 1975, 18, 2-58; J. Brazil. Chem.
Soc. 12, 273-324, 2001).
[0122] The 3-hydroxyoxindoles IV which contain for example in
position 5 an iodine as radical R.sup.a in the 6-membered aromatic
can be converted with KCN or Zn(CN).sub.2 with Pd(0) catalysis in
solvents such as dimethylformamide or tetrahydrofuran and, where
appropriate also with the addition of bases such as K.sub.2CO.sub.3
or other carbonates or amines, at elevated temperature into the
analogous cyan-containing 3-hydroxyoxindole IV. It is possible to
take as Pd(0) salts for example transition metal complexes prepared
in situ from PdCl.sub.2 or PdOAc.sub.2 by adding phosphines such as
tris(ortho-tolyl)phosphine. Commercial palladium complexes such as,
for example, the catalyst tetrakis(triphenylphosphine)palladium(0)
and/or additions of phosphine ligands can likewise be employed.
[0123] The hydroxy group in the compound IV is then derivatized,
for example with phenyl chloroformate, to give the compounds Va
and/or Vb. This consequently takes place by reaction with reagents
such as, for example, carboxylic acids, carbonyl chlorides,
carbonic anhydrides, chloroformates, isocyanates or carbamoyl
chlorides into the compounds V of the invention, using generally
customary methods (see J. March, Advanced Organic Chemistry, 1992,
4th edition, Wiley, New York, pages 417-421; 499; 903). For
example, LG can have as leaving group OPh in the compounds Va
and/or Vb which is derived from reaction of IV with phenyl
chloroformate in the presence of a base such as, for example,
pyridine.
[0124] Subsequent reaction with excess amines VI, where appropriate
at elevated temperature and/or with the addition of auxiliary bases
such as, for example, triethylamine or diisopropylethylamine, leads
to the compounds VII. The amines VI can be either purchased or
prepared by methods known from the literature.
[0125] Compounds such as VII can then be converted by treatment
with sulfonyl chlorides VIII after deprotonation with a strong base
such as, for example, potassium tert-butoxide or sodium hydride in
dimethylformamide (DMF) into the compounds of the invention. The
employed sulfonyl chlorides VIII can either be purchased or
prepared in an analogous manner to known processes (see, for
example, J. Med. Chem. 40, 1149 (1997)).
##STR00002##
[0126] Alternatively, the compounds I of the invention can be
prepared according to synthesis scheme 2 in the shown three-stage
process analogous to synthesis scheme 1 with alteration of the
sequence.
[0127] In this case firstly the 3-hydroxyoxindoles IV are
sulfonylated by deprotonation with a strong base such as, for
example, sodium hydride or potassium tert-butoxide and subsequent
treatment with sulfonyl chlorides VIII in DMF. In the next step,
derivatization of the hydroxy group in IX follows to give the
compound X by treatment for example with phenyl chloroformate.
Finally, the compounds I of the invention are generated in an
excess of amine VI or else with the assistance of an auxiliary
base.
##STR00003##
[0128] A further preparation possibility and derivatization by
R.sup.3 in the amine VI is represented by the reaction of amines
with aldehydes or ketones in the presence of reducing agents such
as, for example, sodium cyanoborohydride or sodium
acetoxyborohydride in the manner of a reductive amination (J.
March, Advanced Organic Chemistry, 1992, 4th edition, Wiley, New
York, pages 411; 898).
[0129] A further aspect of the present invention relates to a
pharmaceutical composition comprising at least one compound of the
general formula I and/or a pharmaceutically acceptable salt or a
prodrug thereof as detailed above, and a pharmaceutically
acceptable carrier. Suitable carriers depend inter alia on the
dosage form of the composition and are known in principle to the
skilled worker. Some suitable carriers are described
hereinafter.
[0130] A further aspect of the present invention relates to the use
of compounds of the formula I and/or of pharmaceutically acceptable
salts or prodrugs thereof for the manufacture of a medicament for
the treatment and/or prophylaxis of vasopressin-dependent
diseases.
[0131] Vasopressin-dependent diseases are those in which the
progress of the disease is at least partly dependent on
vasopressin, i.e. diseases which show an elevated vasopressin level
which may contribute directly or indirectly to the pathological
condition. In other words, vasopressin-dependent diseases are those
which can be influenced by modulating the vasopressin receptor, for
example by administration of a vasopressin receptor ligand
(agonist, antagonist, partial antagonist/agonist, inverse agonist
etc.).
[0132] In a preferred embodiment, the present invention relates to
the use of compounds of the invention of the formula I or of
pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
diseases selected from diabetes, insulin resistance, nocturnal
enuresis, incontinence and diseases in which impairments of blood
clotting occur, and/or for delaying micturition. The term
"diabetes" means all types of diabetes, especially diabetes
mellitus (including type I and especially type II), diabetes
renalis and in particular diabetes insipidus. The types of diabetes
are preferably diabetes mellitus of type II (with insulin
resistance) or diabetes insipidus.
[0133] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
diseases selected from hypertension, pulmonary hypertension, heart
failure, myocardial infarction, coronary spasm, unstable angina,
PTCA (percutaneous transluminal coronary angioplasty), ischemias of
the heart, impairments of the renal system, edemas, renal
vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia,
Schwartz-Bartter syndrome, impairments of the gastrointestinal
tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal
ulcers, emesis, emesis occurring during chemotherapy, and travel
sickness.
[0134] The compounds of the invention of the formula I or their
pharmaceutically acceptable salts or their prodrugs or the
pharmaceutical composition of the invention can also be used for
the treatment of various vasopressin-dependent complaints which
have central nervous causes or alterations in the HPA axis
(hypothalamic pituitary adrenal axis), for example for affective
disorders such as depressive disorders and bipolar disorders. These
include for example dysthymic disorders, phobias, post-traumatic
stress disorders, general anxiety disorders, panic disorders,
seasonal depression and sleep disorders.
[0135] The compounds of the invention of the formula I and their
pharmaceutically acceptable salts or their prodrugs or the
pharmaceutical composition of the invention can likewise be
employed for the treatment of anxiety disorders and
stress-dependent anxiety disorders, such as, for example,
generalized anxiety disorders, phobias, post-traumatic anxiety
disorders, panic anxiety disorders, obsessive-compulsive anxiety
disorders, acute stress-dependent anxiety disorders and social
phobia.
[0136] The compounds of the invention can furthermore also be
employed for the treatment of memory impairments, Alzheimer's
disease, psychoses, psychotic disorders, sleep disorders and/or
Cushing's syndrome, and all stress-dependent diseases.
[0137] Accordingly, a further preferred embodiment of the present
invention relates to the use of compounds of the invention of the
formula I or of pharmaceutically acceptable salts or prodrugs
thereof for the manufacture of a medicament for the treatment of
affective disorders.
[0138] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of anxiety disorders
and/or stress-dependent anxiety disorders.
[0139] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of memory impairments
and/or Alzheimer's disease.
[0140] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of psychoses and/or
psychotic disorders.
[0141] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of Cushing's syndrome
or other stress-dependent diseases.
[0142] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of sleep
disorders.
[0143] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of depressive
disorders. A particular form of depressive disorders are so-called
childhood onset mood disorders, i.e. depressive moods having their
onset in childhood.
[0144] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment of vasomotor symptoms
and/or thermoregulatory dysfunctions such as, for example, the hot
flush symptom.
[0145] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
drug or pharmaceutical dependencies and/or dependencies mediated by
other factors, for the treatment and/or prophylaxis of stress
caused by withdrawal of one or more factors mediating the
dependence and/or for the treatment and/or prophylaxis of
stress-induced relapses into drug or pharmaceutical dependencies
and/or dependencies mediated by other factors.
[0146] In a further preferred embodiment, the present invention
relates to the use of compounds of the invention of the formula I
or of pharmaceutically acceptable salts or prodrugs thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
schizophrenia and/or psychosis.
[0147] A further aspect of the invention relates to a method for
the treatment and/or prophylaxis of vasopressin-dependent diseases,
in which an effective amount of at least one compound of the
invention of the formula I or of at least one pharmaceutically
acceptable salt or one prodrug thereof or of a pharmaceutical
composition of the invention is administered to a patient.
[0148] Concerning the definition of vasopressin-dependent diseases,
reference is made to the above statements.
[0149] In a preferred embodiment of the invention, the method of
the invention serves for the treatment and/or prophylaxis of
disorders selected from diabetes, insulin resistance, nocturnal
enuresis, incontinence and diseases in which impairments of blood
clotting occur, and/or for delaying micturition. Concerning the
definition of diabetes, reference is made to the above
statements.
[0150] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of disorders
selected from hypertension, pulmonary hypertension, heart failure,
myocardial infarction, coronary spasm, unstable angina, PTCA
(percutaneous transluminal coronary angioplasty), ischemias of the
heart, impairments of the renal system, edemas, renal vasospasm,
necrosis of the renal cortex, hyponatremia, hypokalemia,
Schwartz-Bartter syndrome, impairments of the gastrointestinal
tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal
ulcers, emesis, emesis occurring during chemotherapy, and travel
sickness.
[0151] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of affective
disorders.
[0152] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of anxiety
disorders and/or stress-dependent anxiety disorders.
[0153] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of memory
impairments and/or Alzheimer's disease.
[0154] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of psychoses
and/or psychotic disorders.
[0155] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of Cushing's
syndrome.
[0156] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of sleep
disorders in a patient.
[0157] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of depressive
disorders. In the case of depressive disorders, specific mention is
also to be made of childhood onset mood disorders, i.e. depressive
moods having their onset in childhood.
[0158] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of vasomotor
symptoms and/or thermoregulatory dysfunctions, such as, for
example, the hot flush symptom.
[0159] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of drug or
pharmaceutical dependencies and/or dependencies mediated by other
factors, for the treatment and/or prophylaxis of stress caused by
withdrawal of one or more factors mediating the dependence, and/or
for the treatment and/or prophylaxis of stress-induced relapses
into drug or pharmaceutical dependencies and/or dependencies
mediated by other factors.
[0160] In a further preferred embodiment, the method of the
invention serves for the treatment and/or prophylaxis of
schizophrenia and/or psychosis.
[0161] The patient to be treated prophylactically or
therapeutically with the method of the invention is preferably a
mammal, for example a human or a nonhuman mammal or a nonhuman
transgenic mammal. Specifically it is a human.
[0162] The compounds of the general formula I, their
pharmaceutically acceptable salts and prodrugs as detailed above
can be prepared by a skilled worker with knowledge of the technical
teaching of the invention in implementing and/or in analogous
implementation of process steps known per se.
[0163] The compounds I or their prodrugs and/or their
pharmaceutically acceptable salts are distinguished by having a
selectivity for the vasopressin V1b receptor subtype vis-a-vis at
least one of the closely related vasopressin/oxytocin receptor
subtypes (for example vasopressin V1a, vasopressin V2 and/or
oxytocin).
[0164] Alternatively, or preferably in addition, the compounds I or
their prodrugs and/or their pharmaceutically acceptable salts are
distinguished by having an improved metabolic stability.
[0165] The metabolic stability of a compound can be measured for
example by incubating a solution of this compound with liver
microsomes from particular species (for example rat, dog or human)
and determining the half-life of the compound under these
conditions (R S Obach, Curr Opin Drug Discov Devel. 2001, 4,
36-44). It is possible in this connection to conclude from an
observed longer half-life that the metabolic stability of the
compound is improved. The stability in the presence of human liver
microsomes is of particular interest because it makes it possible
to predict the metabolic degradation of the compound in the human
liver. Compounds with increased metabolic stability (measured in
the liver microsome test) are therefore probably also degraded more
slowly in the liver. The slower metabolic degradation in the liver
may lead to higher and/or longer-lasting concentrations (active
levels) of the compound in the body, so that the elimination
half-life of the compounds of the invention is increased. Increased
and/or longer-lasting active levels may lead to a better activity
of the compound in the treatment or prophylaxis of various
vasopressin-dependent diseases. In addition, an improved metabolic
stability may lead to an increased bioavailability after oral
administration, because the compound is subject, after absorption
in the intestine, to less metabolic degradation in the liver
(so-called first pass effect). An increased oral bioavailability
may, owing to an increased concentration (active level) of the
compound, lead to a better activity of the compound after oral
administration.
[0166] Alternatively, or preferably in addition, the compounds I or
their prodrugs and/or their pharmaceutically acceptable salts are
distinguished by having an improved pharmacological activity,
compared with the oxindole compounds known from the prior art, in
patients or relevant animal models which enable prognostic
statements for use in the treatment.
[0167] The compounds of the invention are effective after
administration by various routes. Possible examples are
intravenous, intramuscular, subcutaneous, topical, intratracheal,
intranasal, transdermal, vaginal, rectal, sublingual, buccal or
oral administration, and administration is frequently intravenous,
intramuscular or, in particular, oral.
[0168] The present invention also relates to pharmaceutical
compositions which comprise an effective dose of a compound I of
the invention, of a pharmaceutically acceptable salt or of a
prodrug thereof and suitable pharmaceutical carriers (drug
carriers).
[0169] These drug carriers are chosen according to the
pharmaceutical form and the desired mode of administration and are
known in principle to the skilled worker.
[0170] The compounds of the invention of the formula I or
optionally suitable salts of these compounds can be used to produce
pharmaceutical compositions for oral, sublingual, buccal,
subcutaneous, intramuscular, intravenous, topical, intratracheal,
intranasal, transdermal, vaginal or rectal administration, and be
administered to animals or humans in uniform administration forms,
mixed with conventional pharmaceutical carriers, for the
prophylaxis or treatment of the above disorders or diseases.
[0171] The suitable administration forms (dose units) include forms
for oral administration such as tablets, gelatin capsules, powders,
granules and solutions or suspensions for oral intake, forms for
sublingual, buccal, intratracheal or intranasal administration,
aerosols, implants, forms of subcutaneous, intramuscular or
intravenous administration and forms of rectal administration.
[0172] The compounds of the invention can be used in creams,
ointments or lotions for topical administration.
[0173] In order to achieve the desired prophylactic or therapeutic
effect, the dose of the active ingredient can vary between 0.01 and
50 mg per kg of body weight and per day.
[0174] Each unit dose may comprise from 0.05 to 5000 mg, preferably
1 to 1000 mg, of the active ingredient in combination with a
pharmaceutical carrier. This unit dose can be administered once to
5 times a day, so that a daily dose of from 0.5 to 25 000 mg,
preferably 1 to 5000 mg, is administered.
[0175] If a solid composition is prepared in the form of tablets,
the active ingredient is mixed with a solid pharmaceutical carrier
such as gelatin, starch, lactose, magnesium stearate, talc, silicon
dioxide or the like.
[0176] The tablets can be coated with sucrose, a cellulose
derivative or another suitable substance or be treated otherwise in
order to display a sustained or delayed activity and to release a
predetermined amount of the active ingredient continuously.
[0177] A preparation in the form of gelatin capsules is obtained by
mixing the active ingredient with an extender and including the
resulting mixture in soft or hard gelatin capsules.
[0178] A preparation in the form of a syrup or elixir or for
administration in the form of drops may contain active ingredients
together with a sweetener, which is preferably calorie-free,
methylparaben or propylparaben as antiseptics, a flavoring and a
suitable coloring substance.
[0179] Water-dispersible powders or granules may comprise the
active ingredients mixed with dispersants, wetting agents or
suspending agents, such as polyvinylpyrrolidones, and sweeteners or
masking flavors.
[0180] Rectal or vaginal administration is achieved by using
suppositories which are prepared with binders which melt at rectal
temperature, for example cocoa butter or polyethylene glycols.
Parenteral administration is effected by using aqueous suspensions,
isotonic saline solutions or sterile and injectable solutions which
comprise pharmacologically acceptable dispersants and/or wetting
agents, for example propylene glycol or polyethylene glycol.
[0181] The active ingredient may also be formulated as
microcapsules or centrosomes, if suitable with one or more carriers
or additives.
[0182] The compositions of the invention may, in addition to the
compounds of the invention, comprise other active ingredients which
may be beneficial for the treatment of the disorders or diseases
indicated above.
[0183] The present invention thus further relates to pharmaceutical
compositions in which a plurality of active ingredients are present
together, where at least one of these is a compound I of the
invention, salt or a prodrug thereof.
[0184] The invention is explained in more detail below by means of
examples, but the examples are not to be understood to be
restrictive.
[0185] The compounds of the invention can be prepared by various
synthetic routes. The methods mentioned, as described accordingly
in synthesis schemes 1 and 2, are explained in greater detail
merely by way of example using the given examples without being
exclusively restricted to synthesis routes 1 or 2 or analogous
methods.
EXPERIMENTAL SECTION
Abbreviations
[0186] THF: tetrahydrofuran [0187] DMSO: dimethyl sulfoxide [0188]
TFA: trifluoroacetic acid [0189] p: pseudo (for example pt pseudo
triplet) [0190] b: broad (for example bs broad singlet) [0191] s:
singlet [0192] d: doublet [0193] t: triplet [0194] m: multiplet
[0195] dd: doublet of doublets [0196] dt: doublet of triplets
[0197] tt: triplet of triplets
I. Preparation of the Starting Compound VI
a) 1-Ethyl-4-piperidin-4-yl-piperazine
a.1) tert-Butyl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0198] 29.2 g (256 mmol) of N-ethylpiperazine were introduced with
50.0 g (256 mmol) of tert-butyl 4-oxopiperidine-1-carboxylate
(corresponds to 1-Boc-4-piperidone) into 800 ml of ethanol while
cooling in ice. 15.4 g (256 mmol) of glacial acetic acid were
added. Then 16.1 g (256 mmol) of sodium acetoxyborohydride were
added in portions to the cooled reaction mixture. Initially slight
gas formation was observed and, after addition of 2/3 of the
reducing agent, foam formation was observed. The reaction mixture
was stirred at room temperature overnight. The reaction solution
was worked up by adding 200 ml of 2N of sodium hydroxide solution
while cooling, distilling out the solvent ethanol and diluting the
remaining reaction mixture with water. It was extracted with
diethyl ether (2.times.) and was washed with saturated sodium
chloride solution (1.times.), and the combined organic phases were
dried over magnesium sulfate and filtered, and the solvent was
removed in vacuo. The crude title compound was obtained as a yellow
oil which was then chromatographed on a 4 l suction funnel filled
with silica gel using dichloromethane and 10% methanol as eluent.
In total, 40 g (135 mmol, 53%) of tert-butyl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate were
obtained.
a.2) 1-Ethyl-4-piperidin-4-ylpiperazine as chloride salt
[0199] The protective group was removed by introducing 40 g (135
mmol) of tert-butyl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate from example a.1
into 200 ml of methanol and 1.8 l of dichloromethane and adding 100
ml of 5-6M HCl solution in isopropanol. A suspension resulted, and
slight gas evolution was also observable. The reaction mixture was
stirred at 40.degree. C. (water bath temperature) for one hour and
then stirred at room temperature for 48 hours. For complete
deprotection, 50 ml of the 5-6M HCl solution in isopropanol were
again added and the reaction mixture was stirred at 40.degree. C.
The dichloromethane was distilled out in a rotary evaporator. 200
ml of methanol and 30 ml of the 5-6M HCl solution in isopropanol
were again added. The reaction mixture was stirred under reflux for
one hour, during which a white suspension formed with strong
evolution of gas. A mobile suspension then resulted and was cooled
to room temperature. The precipitate was filtered off with suction
and washed with methanol and diethyl ether. After drying, 36 g (117
mmol, 87%) of 1-ethyl-4-piperidin-4-ylpiperazine were isolated as
chloride salt.
[0200] .sup.1H-NMR (D.sub.2O, 400 MHz) .delta.[ppm]=3.74-3.47 (m,
11H), 3.28 (q, 2H, J=7.3 Hz), 3.06 (dt, 2H, J=2.2 Hz, J=13.2 Hz),
2.38 (m, 2H, J=13.6 Hz), 1.89 (dq, 2H, J=4.1 Hz, J=13.3 Hz), 1.30
(t, 3H, J=7.3 Hz).
II. Preparation of the Racemic Compounds of the Formula I
Example 1
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
1.1
(.+-.)-3-(2-Ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol--
2-one
[0201] 3.22 g (80.50 mmol, 60% w/w) of sodium hydride were added in
portions to 20.86 g (76.40 mmol) of 5-iodoisatin in 400 ml of
anhydrous tetrahydrofuran (THF) while stirring and cooling in an
ice bath, keeping the temperature at between 0-10.degree. C. The
resulting suspension was stirred while cooling in an ice bath for
one hour. To prepare the pyridine Grignard 20 g (80.30 mmol) of
2-ethoxy-3-iodopyridine were dissolved in 400 ml of anhydrous THF
at room temperature. 95.6 ml (1 M solution in THF, 95.60 mmol) of
ethylmagnesium bromide were added to this solution while cooling at
a temperature between 22 and 15.degree. C. over a period of 5-10
minutes. The solution was stirred for 20 minutes, during which it
became a pale yellowish color from colorless.
[0202] The solution of the pyridine Grignard was then added to the
solution, cooled in an ice bath, of the 5-iodoisatin sodium salt at
a temperature between 5 and 18.degree. C. over a period of 5-10
minutes. After addition of the pyridine Grignard was complete, the
ice bath was removed. The reaction mixture was stirred at room
temperature for 2 hours. An excess of saturated ammonium chloride
solution was added, followed by ethyl acetate, the mixture being
stirred for 5 minutes. The aqueous phase was separated off and
extracted with ethyl acetate (2.times.). The combined organic
phases were washed with water (2.times.), and the solvent was
removed in vacuo. During this, unreacted 5-iodoisatin precipitated
first from the still dilute solution and was separated off. After
further concentration, finally the title compound also
crystallized. The suspension was stored in a refrigerator at
5.degree. C. for 2 hours. The precipitated, pale yellow solid was
then filtered off and washed with a little ethyl acetate. After
drying at 40.degree. C.,
(.+-.)-3-(2-ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol-2-o-
ne (17.1 g, 43.16 mmol, 57%) was isolated.
[0203] ESI-MS [M+H.sup.+]=397.05 calculated for
C.sub.15H.sub.13IN.sub.2O.sub.3=396.19.
1.2
(.+-.)-5-Cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-o-
ne
[0204] 7.1 g (17.92 mmol) of
(.+-.)-3-(2-ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol-2-o-
ne from example 1.1 were stirred in 100 ml of anhydrous THF under a
nitrogen atmosphere at room temperature. 2.1 g (17.92 mmol) of zinc
cyanide were added, followed by 0.51 g (0.45 mmol) of the catalyst
tetrakis(triphenylphosphine)palladium(0). The reaction mixture was
immediately placed in a preheated oil bath at a temperature of
100.degree. C. The mixture was stirred at 100.degree. C. (oil-bath
temperature) and, after 30 minutes, a further 0.51 g (0.45 mmol) of
the catalyst was added. The mixture was stirred for a total of 2
hours. The reaction mixture was allowed to cool to room temperature
and an excess of water was added. It was subsequently extracted
with ethyl acetate (3.times.), and the combined organic phases were
washed with water (3.times.). The solvent was evaporated to dryness
in vacuo, and the residue was slurried with a small volume of ethyl
acetate. A pale yellow solid could be filtered off and was washed
with ethyl acetate and dried in a vacuum drying oven. 3.7 g (12.44
mmol, 69.4%) of
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
were obtained.
[0205] ESI-MS [M+H.sup.+]=296.05 calculated for
C.sub.16H.sub.13N.sub.3O.sub.3=295.30.
1.3 (.+-.)-Phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[(phenoxycarbonyl)oxy]indoline-1-
-carboxylate
[0206] 4.63 ml (36.98 mmol) of phenyl chloroformate were slowly
added dropwise, undiluted, at the preset temperature to a
suspension, cooled to 0.degree. C., of 5.20 g (17.61 mmol) of
(.+-.)-5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
from example 1.2 in 100 ml of pyridine. After the reaction mixture
had thawed to room temperature it was stirred for 2 hours. The
progress of the reaction was followed by thin-layer chromatography
(silica gel, dichloromethane/methanol 9:1). Excess pyridine was
removed in vacuo, and the residue was poured into 200 ml of
ice-water and extracted with ethyl acetate (3.times.). The organic
phase was washed with water (2.times.). Traces of pyridine were
still present in the phase. The organic phase was dried over sodium
sulfate. After removal of the ethyl acetate in vacuo, the remaining
pyridine was driven off by addition of toluene and removal in vacuo
several times. The residue was dried under high vacuum. 8.20 g
(15.31 mmol, 87%) of phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[(phenoxycarbonyl)-oxy]indoline--
1-carboxylate were obtained.
[0207] ESI-MS [M+H.sup.+]=536.25 calculated for
C.sub.30H.sub.21N.sub.3O.sub.7=535.52.
1.4
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-y-
l 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0208] 2.74 g (14.94 mmol) of 1-(1-methylpiperidin-4-yl)piperazine
were added to a solution of 1.60 g (2.89 mmol) of (.+-.)-phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[(phenoxycarbonyl)oxy]indoline-1-
-carboxylate from example 1.3 in 50 ml of THF. During this,
initially a slight turbidity formed and eventually a precipitate
separated out. After stirring at room temperature for 2 hours, the
reaction was complete (checked by thin-layer chromatography (silica
gel, dichloromethane/methanol 9:1)). The mixture was stirred
overnight. The precipitate was filtered off with suction and washed
with THF and diethyl ether. 0.923 g (1.829 mmol, 61%) of
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate was obtained.
The title compound was pure according to MS and HPLC. The mother
liquor contained only traces of the title compound plus the
byproduct phenyl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate.
[0209] ESI-MS [M+H.sup.+]=505.25 calculated for
C.sub.27H.sub.32N.sub.6O.sub.4=504.59.
1.5
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3--
yl)-2-oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0210] 24.47 mg (0.22 mmol) of potassium tert-butoxide were added
undiluted to a solution of 100 mg (0.20 mmol) of
(.+-.)-5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate in 2 ml of
absolute dimethylformamide while cooling at 0.degree. C. The
reaction mixture was stirred at 0.degree. C. for one hour. A clear
colorless solution formed. At 0.degree. C., 51.6 mg (0.22 mmol) of
2,4-dimethoxybenzenesulfonyl chloride were added. The reaction
mixture was allowed to thaw to room temperature and was stirred at
room temperature overnight. After conversion was complete, the
reaction mixture was poured into 10 ml of ice-water and initially
neutralized and then adjusted to pH 9 with 2 ml of 1 N sodium
hydroxide solution. A precipitate separated out and was washed with
water and dried in a vacuum drying oven to result in 68 mg of dry
solid. In order to remove the slight impurities, the solid was
stirred in 3 ml of diethyl ether. After leaving to stand overnight,
the solid was again filtered off and washed with a little diethyl
ether and dried. 40 mg (0.06 mmol, 29%) of
(.+-.)-5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate were
obtained.
[0211] ESI-MS [M+H.sup.+]=705.4 calculated for
C.sub.35H.sub.40N.sub.6O.sub.8S=704.81.
[0212] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.
[ppm]=8.22-8.10 (m, 2H), 7.96 (d, 1H, J=8.0 Hz), 7.92 (d, 1H, J=8.3
Hz), 7.85 (d, 1H, J=8.7 Hz), 7.65 (s, 1H), 7.13 (m, 1H), 6.67-6.63
(m, 2H), 4.08 (m, 2H), 3.84 (s, 3H), 3.67-3.45 (m, 3H), 3.51 (s,
3H), 3.04 (m, 2H), 2.74 (pd, 2H, J=9.4 Hz), 2.46 (m, 1H), 2.28 (m,
2H), 2.14 (m, 1H), 2.10 (s, 3H), 1.79 (pt, 2H, J=10.3 Hz), 1.61
(pd, 2H, J=10.2 Hz), 1.36 (m, 2H), 0.99 (t, 3H, J=6.4 Hz).
[0213] The compounds I of the invention can also be purified as an
alternative to crystallization by conventional normal-phase column
chromatography (such as, for example, NP SiO.sub.2 cartridge,
Chromabond and dichloromethane/methanol as eluent) and/or by
preparative HPLC (RP, eluent acetonitrile/water, 0.1% TFA or 0.1%
acetic acid). Compounds I then result where appropriate as
trifluoroacetic acid salt, bis(trifluoroacetic acid) salt or acetic
acid salt.
Examples 2 to 90
[0214] The compounds of the formula I according to examples 2 to 90
can be prepared using the appropriate starting compounds in analogy
to the process for preparing example 1.
Example 2
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-ox-
o-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0215] ESI-MS [M+H.sup.+]=675.15 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
Example 4
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihyd-
ro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0216] ESI-MS [M+H.sup.+]=645.20 calculated for
C.sub.33H.sub.36N.sub.6O.sub.6S=644.76.
[0217] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.18-8.15
(m, 2H), 8.05 (d, 2H, J=7.5 Hz), 7.97 (d, 1H, J=8.6 Hz), 7.93 (dd,
1H, J=1.7 Hz, J=8.6 Hz), 7.79 (pt, 1H, J=7.5 Hz), 7.70 (pd, 1H,
J=1.6 Hz), 7.66 (pt, 2H, J=7.9 Hz), 7.15 (dd, 1H, J=5.1 Hz, J=7.5
Hz), 4.05 (m, 1H), 3.88 (m, 1H), 3.55 (m, 2H), 3.03 (m, 2H), 2.97
(m, 2H), 2.47-2.21 (m, 10H), 1.74 (m, 2H), 1.51 (m, 2H), 0.89 (t,
3H, J=7.1 Hz).
Example 5
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-ox-
o-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0218] ESI-MS [M+H.sup.+]=675.15 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
Example 10
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihyd-
ro-1H-indol-3-yl 4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate,
trifluoroacetic acid salt
[0219] 4 .mu.l (0.06 mmol) of acetaldehyde were added dropwise to
50 mg (0.06 mmol) of
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate in the form of
the bis(trifluoroacetic acid) salt from example 28 in 5 ml of
dimethylformamide. The mixture was stirred for 5 minutes. To this
suspension were added firstly 41.3 mg (0.29 mmol) of sodium sulfate
and then 10 .mu.l (0.12 mmol) of glacial acetic acid, and the
mixture was stirred for one hour. 18.5 mg (0.09 mmol) of sodium
acetoxyborohydride were introduced in one portion, whereupon an
almost clear solution formed within 15 minutes. The progress of the
reaction was followed by LC-MS (RP, acetonitrile/water as eluent
and 0.1% TFA). After conversion was complete, the mixture was
diluted with water and adjusted to pH 10 with 2N sodium hydroxide
solution. After removal of the organic phase, the aqueous phase was
extracted again with dichloromethane (2.times.), the combined
organic phase was dried over magnesium sulfate and filtered, and
the solvent was removed in vacuo. 35 mg of the crude title compound
were isolated and were purified by preparative HPLC on a chromolith
column (normal phase, from Merck) with the eluents dichloromethane
and methanol (gradient 0-5% by volume of methanol within 15 min).
Since byproduct (the desulfonylated analog of the product) was
detectable in addition to the title compound, it was purified again
by preparative HPLC (RP, eluent acetonitrile/water, 0.1% TFA). 19
mg (0.027 mmol, 45%) of
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-yl 4-(1-ethylpiperidin-4-yl)piperazine-1-carboxylate,
trifluoroacetic acid salt were isolated.
[0220] ESI-MS [M+H.sup.+]=659.3 calculated for
C.sub.34H.sub.38N.sub.6O.sub.6S=658.78.
Example 25
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-dihydro-1H-indol-3-yl
4-piperidin-4-ylpiperazine-1-carboxylate as bis(trifluoroacetic
acid) salt
[0221] 0.159 mg (1.391 mmol) of trifluoroacetic acid was added
dropwise to a solution of 0.220 g (0.278 mmol) of
5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo--
2,3-dihydro-1H-indol-3-yl-4-[1-(tert-butoxycarbonyl)piperidine-4-yl]pipera-
zine-1-carboxylate (prepared in analogy to example 1, process stage
1.1) to 1.5)) in 3 ml of dichloromethane. The reaction mixture was
stirred at room temperature for one hour, monitoring the reaction
by thin-layer chromatography (dichloromethane/methanol 9:1). The
solvent was removed in vacuo, and the residue (304 mg) was then
purified by preparative HPLC (RP, eluent acetonitrile/water, 0.1%
TFA), with 20 mg (0.022 mol, 8%) of
5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo--
2,3-dihydro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate
as bis(trifluoroacetic acid) salt being isolated.
[0222] ESI-MS [M+H.sup.+]=691.25 calculated for
C.sub.34H.sub.38N.sub.6O.sub.8S=690.78.
Example 28
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihyd-
ro-1H-indol-3-yl 4-piperidin-4-ylpiperazine-1-carboxylate as
bis(trifluoroacetic acid) salt
[0223] ESI-MS [M+H.sup.+]=631.20 calculated for
C.sub.32H.sub.34N.sub.6O.sub.6S=630.73.
Example 31
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
[0224] ESI-MS [M+H.sup.+]=705.25 calculated for
C.sub.35H.sub.40N.sub.6O.sub.8S=704.81.
Example 32
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-ox-
o-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
[0225] ESI-MS [M+H.sup.+]=675.15 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
Example 34
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihyd-
ro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
[0226] ESI-MS [M+H.sup.+]=645.15 calculated for
C.sub.33H.sub.36N.sub.6O.sub.6S=644.76.
Example 35
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulfonyl]-2-ox-
o-2,3-dihydro-1H-indol-3-yl
4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate
[0227] ESI-MS [M+H.sup.+]=675.25 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
Example 37
(.+-.)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0228] ESI-MS [M+H.sup.+]=719.30 calculated for
C.sub.36H.sub.42N.sub.6O.sub.8S=718.84.
[0229] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.19 (dd,
1H, J=1.6 Hz, J=4.9 Hz, 8.15 (dd, 1H, J=1.6 Hz, J=7.6 Hz), 7.97 (m,
2H), 7.87 (d, 1H, J=8.7 Hz), 7.69 (m, 1H), 7.16 (dd, 1H, J=5.0 Hz,
J=7.6 Hz), 6.72-6.68 (m, 2H), 4.19 (m, 1H), 4.10 (m, 2H), 3.86 (s,
3H), 3.74 (m, 2H), 3.52 (s, 3H), 3.58-3.50 (m, 2H), 3.08-2.44 (m,
11H), 1.57 (m, 3H), 1.18 (m, 3H), 1.01 (t, 3H, J=6.8 Hz).
Example 40
(.+-.)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihyd-
ro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0230] ESI-MS [M+H.sup.+]=659.30 calculated for
C.sub.34H.sub.38N.sub.6O.sub.6S=658.78.
[0231] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.19-8.17
(m, 2H), 8.07 (d, 2H, J=7.7 Hz), 7.99 (d, 1H, J=8.6 Hz), 7.95 (m,
1H, J=8.4 Hz), 7.81 (t, 1H, J=7.5 Hz), 7.73 (d, 1H, J=32.5 Hz),
7.67 (pt, 2H, J=7.8 Hz), 7.17 (dd, 1H, J=5.0 Hz, J=7.6 Hz),
4.18-4.04 (m, 2H), 3.92 (m, 1H), 3.43 (m, 2H), 3.01 (m, 1H), 2.62
(m, 1H), 2.45-2.25 (m, 11H), 1.79 (m, 1H), 1.61 (m, 1H), 1.36 (m,
1H), 1.09 (m, 1H), 0.97 (m, 3H), 0.92 (t, 3H, J=7.1 Hz).
Example 55
5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2-
,3-dihydro-1H-indol-3-yl 4-piperazin-1-ylpiperidine-1-carboxylate
as bis(trifluoroacetic acid) salt
[0232] ESI-MS [M+H.sup.+]=691.25 calculated for
C.sub.34H.sub.38N.sub.6O.sub.8S=690.78.
III. Preparation of Chiral Compounds of the General Formula I
A.) Racemate Resolution of Compounds of the Formula I
[0233] Racemic compounds of the formula I can be resolved for
example by separation on a preparative chiral column.
Example 1A and Example 1B
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate (example 1A)
and
(-)-5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate (example 1B)
[0234] 68 mg (0.096 mmol) of the racemic
5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo--
2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate from example 1
were resolved on a preparative chiral column (Chiracel OD, flow
rate 55 ml/min) with n-heptane/ethanol (700:300) as eluent. The
enantiomer eluted first (example 1A) with positive rotation
(rotation determined in chloroform) could be isolated in a yield of
20 mg (0.028 mmol, 29%), and the subsequent enantiomer (example 1B)
with negative rotation (rotation determined in chloroform) could be
isolated in a yield of 17 mg (0.024 mmol, 25%).
Example 1A
(+)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0235] ESI-MS [M+H.sup.+]=353.4 (1/2 mass) calculated for
C.sub.35H.sub.40N.sub.6O.sub.8S=704.81.
[0236] HPLC (Chiracel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=9.10 min.
[0237] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=plus rotation
[0238] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.16 (dd,
1H, J=1.7 Hz, J=4.9 Hz), 8.12 (dd, 1H, J=1.7 Hz, J=7.6 Hz),
7.97-7.91 (m, 2H), 7.85 (pd, 1H, J=8.8 Hz), 7.66 (d, 1H, J=36.9
Hz), 7.13 (dd, 1H, J=5.0 Hz, J=7.6 Hz), 6.66 (m, 2H), 4.15 (m, 1H),
4.09 (q, 2H, J=6.9 Hz), 3.84 (s, 3H), 3.53-3.48 (m, 1H), 3.50 (s,
3H), 2.97 (pt, 1H, J=12.1 Hz), 2.62 (pt, 1H, J=12.6 Hz), 2.40-2.25
(m, 9H), 2.11 (s, 3H), 1.74 (m, 1H), 1.58 (m, 1H), 1.37-1.26 (m,
1H), 1.04 (m, 1H), 1.00 (t, 3H, J=7.1 Hz).
Example 1B
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0239] ESI-MS [M+H.sup.+]=353.45 (1/2 mass) calculated for
C.sub.35H.sub.40N.sub.6O.sub.8S=704.81.
[0240] HPLC (Chiracel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=15.91 min.
[0241] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=minus rotation
[0242] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.17 (dd,
1H, J=1.7 Hz, J=4.9 Hz), 8.12 (dd, 1H, J=1.7 Hz, J=7.6 Hz),
7.97-7.91 (m, 2H), 7.84 (pd, 1H, J=8.5 Hz), 7.66 (d, 1H, J=37.5
Hz), 7.14 (dd, 1H, J=5.0 Hz, J=7.6 Hz), 6.66 (m, 2H), 4.15 (m, 1H),
4.08 (q, 2H, J=6.9 Hz), 3.84 (s, 3H), 3.51 (s+m, 4H), 2.98 (pt, 1H,
J=12.0 Hz), 2.62 (pt, 1H, J=11.1 Hz), 2.47-2.21 (m, 9H), 2.12 (s,
3H), 1.74 (m, 1H), 1.57 (m, 1H), 1.40-1.23 (m, 1H), 1.04 (m, 1H),
1.00 (t, 3H, J=7.1 Hz).
[0243] The racemates of examples 2 to 90 can be resolved in an
analogous manner to result in the corresponding (+) enantiomers 2A,
3A, 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A,
18A, 19A, 20A, 21A, 22A, 23A, 24A, 25A, 26A, 27A, 28A, 29A, 30A,
31A, 32A, 33A, 34A, 35A, 36A, 37A, 38A, 39A, 40A, 41A, 42A, 43A,
44A, 45A, 46A, 47A, 48A, 49A, 50A, 51A, 52A, 53A, 54A, 55A, 56A,
57A, 58A, 59A, 60A, 61A, 62A, 63A, 64A, 65A, 66A, 67A, 68A, 69A,
70A, 71A, 72A, 73A, 74A, 75A, 76A, 77A, 78A, 79A, 80A, 81A, 82A,
83A, 84A, 85A, 86A, 87A, 88A, 89A and 90A
and the corresponding (-) enantiomers 2B, 3B, 4B, 5B, 6B, 7B, 8B,
9B, 10B, 11B, 12B, 13B, 14B, 15B, 16B, 17B, 18B, 19B, 20B, 21B,
22B, 23B, 24B, 25B, 26B, 27B, 28B, 29B, 30B, 31B, 32B, 33B, 34B,
35B, 36B, 37B, 38B, 39B, 40B, 41B, 42B, 43B, 44B, 45B, 46B, 47B,
48B, 49B, 50B, 51B, 52B, 53B, 54B, 55B, 56B, 57B, 58B, 59B, 60B,
61B, 62B, 63B, 64B, 65B, 66B, 67B, 68B, 69B, 70B, 71B, 72B, 73B,
74B, 75B, 76B, 77B, 78B, 79B, 80B, 81B, 82B, 83B, 84B, 85B, 86B,
87B, 88B, 89B and 90B.
Example 2A
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0244] ESI-MS [M+H.sup.+]=675.20 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
[0245] HPLC (Chiracel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=10.10 min.
[0246] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=plus rotation
Example 2B
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0247] ESI-MS [M+H.sup.+]=675.20 calculated for
C.sub.34H.sub.38N.sub.6O.sub.7S=674.78.
[0248] HPLC (Chiracel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.1=12.73 min. (ee=80%)
[0249] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=minus rotation
B.) Synthesis of the (+) and (-) Enantiomers of the Compound of the
Formula I Using Enantiopure Precursors and Intermediates
[0250] The (+) enantiomer of the formula I and the (-) enantiomer
of the formula I can also be prepared using enantiopure precursors
and intermediates for example in analogy to synthesis scheme 1 or
2, preferably in accordance with synthesis scheme 2. The enantiomer
separation is to be explained in detail in relation to intermediate
IV, racemic
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one-
, without being restricted thereto. Resolution of the racemate into
the enantiomers can take place by preparative chiral
chromatography.
[0251] Resolution of racemic
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one:
[0252] After chromatographic separation of 10.0 g (33.86 mmol) of
the racemic
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
from example 1.2, 4.85 g (16.42 mmol) of
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
eluting first (minus rotation, rotation determined in chloroform)
were isolated with an enantiomeric excess (e.e.) of >99% and
4.66 g (15.78 mmol) of
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
eluting last (plus rotation, rotation determined in chloroform)
were isolated with an enantiomeric excess (e.e.) of 99%. The
enantiomer separation conditions were a preparative chiral column
(Chiralpak AD 20 micron 5 cm ID.times.500 cm) with the eluents
hexane/ethanol/methanol in the ratio 80/10/10 and a flow rate of 80
ml/min.
[0253] Enantiomer 1 of
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one:
[0254] ESI-MS [M+H.sup.+]=296.15 calculated for
C.sub.16H.sub.13N.sub.3O.sub.3=295.30.
[0255] HPLC (Chiralpak AD 4.6 mmID.times.25 cm;
hexane/ethanol/methanol 80/10/10) R.sub.f=4.61 min.
[0256] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=minus rotation
[0257] Enantiomer 2 of
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one:
[0258] ESI-MS [M+H.sup.+]=296.15 calculated for
C.sub.16H.sub.13N.sub.3O.sub.3=295.30.
[0259] HPLC (Chiralpak AD 4.6 mmID.times.25 cm;
hexane/ethanol/methanol 80/10/10) R.sub.f=6.43 min.
[0260] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=plus rotation
[0261] Example 4B illustrates by way of example the synthesis route
in analogy to synthesis scheme 2.
Example 4B
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro--
1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
4B.1)
3-(2-Ethoxypyridin-3-yl)-3-hydroxy-2-oxo-1-(phenylsulfonyl)indoline--
5-carbonitrile
[0262] 2.50 g (7.79 mmol) of
(-)-5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
(prepared as in example 1.2 and racemate resolution into the
corresponding enantiomers as described above) were dissolved in 30
ml of dimethylformamide, resulting in a yellow solution. After
cooling to 0.degree. C., 1.00 g (8.94 mmol) of potassium
tert-butoxide was added in portions so that the temperature was
kept between 0.degree. C. and 5.degree. C. The solution changed in
color from yellow to dark yellow. It was stirred for 30 minutes
and, at 0.degree. C., 1.07 ml (8.20 mmol) of benzenesulfonyl
chloride were slowly added dropwise. The solution became turbid and
pale orange in color. It was stirred while cooling in ice for one
hour. The progress of the reaction was followed by thin-layer
chromatography (dichloromethane/methanol 9:1). For working up, the
reaction mixture was added dropwise to ice-water. During this, a
precipitate separated out and was, after stirring for 5 minutes,
filtered off and washed with water. The title compound (2.65 g,
6.09 mmol, 78%) was dried in a vacuum drying oven at 40.degree. C.
and used for the next reaction without further purification.
[0263] ESI-MS [M+H.sup.+]=436.05 calculated for
C.sub.22H.sub.17N.sub.3O.sub.5S=435.46.
4B.2)
5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydr-
o-1H-indol-3-yl phenyl carbonate
[0264] 2.65 g (6.09 mmol) of optically active
3-(2-ethoxypyridin-3-yl)-3-hydroxy-2-oxo-1-(phenylsulfonyl)indoline-5-car-
bonitrile from example 4B.1 were dissolved in 4.9 ml of pyridine
and 6.0 ml of dichloromethane while cooling at 0.degree. C. in ice,
the solution becoming brown in color. At this temperature, 1.24 g
(7.91 mmol) of phenyl chloroformate were slowly added dropwise. The
reaction mixture was stirred in an ice bath for 2 hours. After
conversion was complete, the reaction mixture was further diluted
with dichloromethane and poured into ice-water. The phases were
separated, and the organic phase was washed again with saturated
sodium chloride solution (1.times.) and water (1.times.). The
solvent was evaporated in vacuo, and excess pyridine was removed by
codistillation with toluene. 50 ml of diisopropyl ether were added
to precipitate the product, and, after the solid had been filtered
off with suction and washed with diisopropyl ether, a total of 2.16
g (3.89 mmol, 64%) of the optically active
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-yl phenyl carbonate was isolated. Further purification of
the mother liquor by normal-phase chromatography with
dichloromethane as mobile phase resulted in 800 mg of the optically
active
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-ylphenyl carbonate.
[0265] ESI-MS [M+H.sup.+]=556.15 calculated for
C.sub.29H.sub.21N.sub.3O.sub.7S=555.57.
4B.3)
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-di-
hydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
[0266] 1.29 g (7.02 mmol) of 1-(1-methylpiperidin-4-yl)piperazine
were added to a solution of 1.30 g (2.34 mmol) of optically active
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-yl phenyl carbonate from example 4B.2 in 10 ml of dry
tetrahydrofuran (dried over molecular sieves). The reaction mixture
was initially stirred at room temperature for one hour, then again
heated to 40.degree. C. until complete conversion was achieved in
the reaction. The solvent was removed in vacuo, and the residue was
again dissolved in 100 ml of dichloromethane and extracted with
water (4.times.). Saturated sodium chloride solution was added
dropwise to improve phase separation. The combined organic phase
was dried over magnesium sulfate and filtered, and the solvent was
removed in vacuo. 1.5 g of a yellow-brown foam were obtained and
were again mixed with 1 ml of dichloromethane and 30 ml of diethyl
ether. Stirring resulted in a solid precipitate which was filtered
off with suction. The crystals were purified by column
chromatography on a preparative MPLC (ISCO Companion, 12 g NP
cartridge) with dichloromethane/methanol as eluent. In total, 0.547
g (0.848 mmol, 36%) of
(-)-5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-
-dihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate was obtained.
The mother liquor likewise contained product which was also
purified by crystallization and chromatography.
[0267] In order to obtain the product also as mesylate salt, 18.41
mg (0.19 mmol) of methanesulfonic acid were added to a solution of
130 mg (0.20 mmol) of
(-)-5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-
-1H-indol-3-yl 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
in 5 ml of dichloromethane. The reaction mixture was stirred for
one hour. The solvent was evaporated in vacuo and the residue was
dried over a nitrogen atmosphere. Last traces of solvent were
removed by drying in a vacuum drying oven at 35.degree. C. In
total, 142 mg (0.19 mmol) of the optically active
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro-1H--
indol-3-yl 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate
mesylate were obtained.
[0268] ESI-MS [M+H.sup.+]=645.25 calculated for
C.sub.33H.sub.36N.sub.6O.sub.6S=644.76.
[0269] Rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3, 1
mg/ml)=minus rotation
[0270] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.18 (m,
2H), 8.07 (d, 2H, J=7.5 Hz), 7.99 (d, 1H, J=8.6 Hz), 7.94 (dd, 1H,
J=1.7 Hz, J=8.6 Hz), 7.79 (t, 1H, J=7.5 Hz), 7.71 (d, 1H, J=1.5
Hz), 7.66 (t, 2H, J=7.9 Hz), 7.15 (dd, 1H, J=5.6 Hz, J=7.0 Hz),
4.06 (m, 1H), 3.91 (m, 1H), 3.57 (m, 2H), 2.98 (m, 2H), 2.78 (pd,
2H, J=11.3 Hz), 2.47 (m, 2H), 2.29 (m, 2H), 2.18-2.11 (m, 1H), 2.14
(s, 3H), 1.85 (pt, 2H, J=11.3 Hz), 1.64 (pd, 2H, J=11.7 Hz), 1.39
(m, 2H), 0.92 (t, 3H, J=7.1 Hz).
[0271] The compounds of examples 37B and 40B can be prepared using
the appropriate starting compounds in analogy to the process for
preparing example 4B.
Example 37B
(-)-5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0272] ESI-MS [M+H.sup.+]=719.25 calculated for
C.sub.36H.sub.42N.sub.6O.sub.8S=718.84.
[0273] HPLC (Chiracel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=11.65 min. (ee=80%)
Example 40B
(-)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro--
1H-indol-3-yl 4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0274] ESI-MS [M+H.sup.+]=659.25 calculated for
C.sub.34H.sub.38N.sub.6O.sub.6S=658.78.
[0275] .sup.1H-NMR ([d.sub.6]-DMSO, 500 MHz) .delta.[ppm]=8.24-8.19
(m, 2H), 8.10 (d, 2H, J=7.7 Hz), 8.03 (d, 1H, J=8.6 Hz), 7.97 (m,
1H, J=8.5 Hz), 7.83 (t, 1H, J=7.5 Hz), 7.75 (d, 1H, J=31.6 Hz),
7.70 (pt, 2H, J=7.9 Hz), 7.20 (dd, 1H, J=5.1 Hz, J=7.5 Hz),
4.21-4.08 (m, 2H), 3.97 (m, 1H), 3.44 (m, 2H), 3.05 (m, 1H), 2.64
(m, 1H), 2.48-2.28 (m, 11H), 1.83 (m, 1H), 1.65 (m, 1H), 1.41 (m,
1H), 1.13 (m, 1H), 1.01 (m, 3H), 0.97 (t, 3H, J=7.1 Hz).
[0276]
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-d-
ihydro-1H-indol-3-yl
4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate, example 4A, can
be obtained in analogy to example 4B starting from enantiopure
(+)-5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
(enantiomer with plus rotation [rotation determined in chloroform])
and according to process stages 4B.1) to 4B.3) as enantiomer
4A.
Example 4A
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro--
1H-indol-3-yl 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylate as
trifluoroacetic acid salt
[0277] ESI-MS [M+H.sup.+]=645.25 calculated for
C.sub.33H.sub.36N.sub.6O.sub.6S=644.76.
[0278] The compound of example 40A can be prepared using the
appropriate starting compounds in analogy to the process for
preparing example 4A.
Example 40A
(+)-5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulfonyl)-2,3-dihydro--
1H-indol-3-yl 4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate as
trifluoroacetic acid salt
[0279] ESI-MS [M+H.sup.+]=659.25 calculated for
C.sub.34H.sub.38N.sub.6O.sub.6S=658.78.
IV. Determination of the Biological Activity
1. Vasopressin V1b Receptor Binding Assay:
Substances:
[0280] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO and further diluted to 5.times.10.sup.-4 M to
5.times.10.sup.-9 M. These serial DMSO predilutions were diluted
1:10 with assay buffer. The substance concentration was further
diluted 1:5 in the assay mixture (2% DMSO in the mixture).
Membrane Preparation:
[0281] CHO-K1 cells with stably expressed human vasopressin V1b
receptor (clone 3H2) were harvested and homogenized in 50 mM
Tris-HCl and in the presence of protease inhibitors (Roche complete
Mini #1836170) using a Polytron homogenizer at intermediate setting
for 2.times.10 seconds, and subsequently centrifuged at 40
000.times.g for 1 h. The membrane pellet was again homogenized and
centrifuged as described and subsequently taken up in 50 mM
Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen in
liquid nitrogen at -190.degree. C.
Binding Assay:
[0282] The binding assay was carried out by the method based on
that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)).
[0283] The incubation buffer was: 50 mM Tris, 10 mM MgCl.sub.2,
0.1% BSA, pH 7.4.
[0284] In the assay mixture (250 .mu.l), membranes (50 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V1b receptors (cell line hV1b_3H2_CHO) were
incubated with 1.5 nM .sup.3H-AVP (8-Arg-vasopressin, PerkinElmer
#18479) in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1%
BSA, pH 7.4) (total binding) or additionally with increasing
concentrations of test substance (displacement experiment). The
nonspecific binding was determined with 1 .mu.M AVP (Bachem #
H1780). All determinations were carried out as triplicate
determinations. After incubation (60 minutes at room temperature),
the free radioligand was filtered off by vacuum filtration (Skatron
cell harvester 7000) through Wathman GF/B glass fiber filter mats,
and the filters were transferred into scintillation vials. The
liquid scintillation measurement took place in a model 2000 or
2200CA Tricarb instrument (Packard). Conversion of the measured cpm
into dpm was carried out with the aid of a standard quench
series.
Analysis:
[0285] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.3H-AVP for
the recombinant human V1b receptors is 0.4 nM and was used to
determine the Ki.
2. Vasopressin Via Receptor Binding Assay:
Substances:
[0286] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO. Further dilution of these DMSO solutions took
place in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA,
pH 7.4).
Membrane Preparation:
[0287] CHO-K1 cells with stably expressed human vasopressin V1a
receptor (clone 5) were harvested and homogenized in 50 mM Tris-HCl
and in the presence of protease inhibitors (Roche complete Mini
#1836170) using a Polytron homogenizer at intermediate setting for
2.times.10 seconds, and subsequently centrifuged at 40 000.times.g
for 1 h. The membrane pellet was again homogenized and centrifuged
as described and subsequently taken up in 50 mM Tris-HCl, pH 7.4,
homogenized and stored in aliquots frozen in liquid nitrogen at
-190.degree. C.
Binding Assay:
[0288] The binding assay was carried out by the method based on
that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)).
[0289] The incubation buffer was: 50 mM Tris, 10 mM MgCl.sub.2,
0.1% BSA, pH 7.4.
[0290] In the assay mixture (250 .mu.l), membranes (20 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V1a receptors (cell line hV1a_5_CHO) were incubated
with 0.04 nM .sup.125I-AVP (8-Arg-vasopressin, NEX 128) in
incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA, pH 7.4)
(total binding) or additionally with increasing concentrations of
test substance (displacement experiment). The nonspecific binding
was determined with 1 .mu.M AVP (Bachem # H1780). Triplicate
determinations were carried out.
[0291] After incubation (60 minutes at room temperature), the free
radioligand was filtered off by vacuum filtration (Skatron cell
harvester 7000) through Wathman GF/B glass fiber filter mats, and
the filters were transferred into scintillation vials.
[0292] The liquid scintillation measurement took place in a model
2000 or 2200CA Tricarb instrument (Packard). Conversion of the
measured cpm into dpm was carried out with the aid of a standard
quench series.
Analysis:
[0293] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.125I-AVP
for the recombinant hV1a receptors was determined in saturation
experiments. A Kd of 1.33 nM was used to determine the Ki.
3. Vasopressin V2 Receptor Binding Assay:
Substances:
[0294] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO. Further dilution of these DMSO solutions took
place in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA,
pH 7.4).
Membrane Preparation:
[0295] CHO-K1 cells with stably expressed human vasopressin V2
receptor (clone 23) were harvested and homogenized in 50 mM
Tris-HCl and in the presence of protease inhibitors (Roche complete
Mini #1836170) using a Polytron homogenizer at intermediate setting
for 2.times.10 seconds, and subsequently centrifuged at 40
000.times.g for 1 h. The membrane pellet was again homogenized and
centrifuged as described and subsequently taken up in 50 mM
Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen in
liquid nitrogen at -190.degree. C.
Binding Assay:
[0296] The binding assay was carried out by the method based on
that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)).
[0297] The incubation buffer was: 50 mM Tris, 10 mM MgCl.sub.2,
0.1% BSA, pH 7.4.
[0298] In the assay mixture (250 .mu.l), membranes (50 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V2 receptors (cell line hV2_23_CHO) were incubated
with 1-2 nM .sup.3H-AVP (8-Arg-vasopressin, PerkinElmer #18479) in
incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA, pH 7.4)
(total binding) or additionally with increasing concentrations of
test substance (displacement experiment). The nonspecific binding
was determined with 1 .mu.M AVP (Bachem # H1780). Triplicate
determinations were carried out.
[0299] After incubation (60 minutes at room temperature), the free
radioligand was filtered off by vacuum filtration (Skatron cell
harvester 7000) through Wathman GF/B glass fiber filter mats, and
the filters were transferred into scintillation vials.
[0300] The liquid scintillation measurement took place in a model
2000 or 2200CA Tricarb instrument (Packard). Conversion of the
measured cpm into dpm was carried out with the aid of a standard
quench series.
Analysis:
[0301] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.3H-AVP for
the recombinant hV2 receptors is 2.4 nM and was used to determine
the Ki.
4. Oxytocin Receptor Binding Assay
Substances:
[0302] The substances were dissolved in a concentration of
10.sup.-2 M in DMSO and diluted with incubation buffer (50 mM Tris,
10 mM MgCl.sub.2, 0.1% BSA, pH 7.4).
Cell Preparation:
[0303] Confluent HEK-293 cells with transiently expressing
recombinant human oxytocin receptors were centrifuged at
750.times.g at room temperature for 5 minutes. The residue was
taken up in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH
7.4 and Roche complete protease inhibitor) and subjected to an
osmotic shock at 4.degree. C. for 20 minutes. The lyzed cells were
then centrifuged at 750.times.g at 4.degree. C. for 20 minutes, the
residue was taken up in incubation buffer, and aliquots of 10.sup.7
cells/ml were prepared. The aliquots were frozen at -80.degree. C.
until used.
Binding Assay:
[0304] On the day of the experiment, the cells were thawed, diluted
with incubation buffer and homogenized using a Multipette Combitip
(Eppendorf, Hamburg). The reaction mixture of 0.250 ml was composed
of 2 to 5.times.10.sup.4 recombinant cells, 3-4 nM .sup.3H-oxytocin
(PerkinElmer, NET 858) in the presence of test substance
(inhibition plot) or only incubation buffer (total binding). The
nonspecific binding was determined with 10.sup.-6 M oxytocin
(Bachem AG, H2510). Triplicate determinations were set up. Bound
and free radioligand were separated by filtration under vacuum with
Whatman GF/B glass fiber filters with the aid of a Skatron cell
harvester 7000. The bound radioactivity was determined by liquid
scintillation measurement in a Tricarb Beta counter, model 2000 or
2200CA (Packard).
Analysis:
[0305] The binding parameters were calculated by nonlinear
regression analysis (SAS) in analogy to the LIGAND program of
Munson and Rodbard (Analytical Biochem 1980; 107: 220-239). The Kd
of .sup.3H-oxytocin for the recombinant hOT receptors is 7.6 nM and
was used to determine the Ki.
5. Determination of the Microsomal Half-Life:
[0306] The metabolic stability of the compounds of the invention
was determined in the following assay.
[0307] The test substances were incubated in a concentration of 0.5
.mu.M as follows:
[0308] 0.5 .mu.M test substance are preincubated together with
liver microsomes from different species (from rat, human or other
species) (0.25 mg of microsomal protein/ml) in 0.05 M potassium
phosphate buffer of pH 7.4 in microtiter plates at 37.degree. C.
for 5 min. The reaction is started by adding NADPH (1 mg/mL). After
0, 5, 10, 15, 20 and 30 min, 50 .mu.l aliquots are removed, and the
reaction is immediately stopped and cooled with the same volume of
acetonitrile. The samples are frozen until analyzed. The remaining
concentration of undegraded test substance is determined by MSMS.
The half-life (T1/2) is determined from the gradient of the signal
of test substance/unit time plot, it being possible to calculate
the half-life of the test substance, assuming first order kinetics,
from the decrease in the concentration of the compound with time.
The microsomal clearance (mCl) is calculated from
mCl=In2/T1/2/(content of microsomal protein in mg/ml).times.1000
[ml/min/mg] (modified from references: Di, The Society for
Biomoleculur Screening, 2003, 453-462; Obach, D M D, 1999 vol 27. N
11, 1350-1359).
6. Determination of the Plasma Protein Binding (PPB) by Equilibrium
Dialysis:
[0309] 150 .mu.l of rat or human plasma to which 1 or 10 .mu.M of
test substance was added is pipetted on one side of the 96-well
dialysis chambers, and 150 .mu.l of PPS buffer are pipetted on the
other side. The chambers are separated by a dialysis membrane with
a cut-off of 6-8000 daltons. The 96-well dialysis chambers are
covered and shaken gently overnight. The next morning, 10 .mu.l of
plasma are removed and diluted with 90 .mu.l of PPS buffer, and the
protein is precipitated with 200 .mu.l of acetonitrile. The
precipitated protein is centrifuged down and 100 .mu.l of the
supernatant is used for the MSMS analysis. 100 .mu.l are removed
from the buffer side for MSMS analysis. See also the following
reference: Banker, Journal of Pharmaceutical Sciences Vol, 92, 5,
967-974, 2003.
7. Methods for In Vitro Determination of the Cytochrome P450 (CYP)
Inhibition
Luminescent Substrates for 2C9 and 3A4:
[0310] 0.4 mg/ml human liver microsomes are preincubated with the
test substances to be investigated (0-20 .mu.M), the CYP-specific
substrates, in 0.05 M potassium phosphate buffer of pH 7.4 at
37.degree. C. for 10 min. The Cyp-specific substrate for CYP 2C9 is
luciferin H, and for CYP 3A4 is luciferin BE. The reaction is
started by adding NADPH. After incubation at RT for 30 min, the
luciferin detection reagent is added, and the resulting
luminescence signal is measured (modified from reference: Promega,
Technical Bulletin P450-GLO.TM. Assays).
Midazolam CYP 3A4 Time-Dependent Inhibition
[0311] The assay consists of 2 parts. Firstly, the test substance
is preincubated with the liver microsomes (with
NADPH=preincubation, then addition of the substrate; in the second
part the substrate and the test substance are added
simultaneously=coincubation.
Preincubation:
[0312] 0.05 mg/ml microsomal protein (human liver microsomes) are
preincubated with 0-10 .mu.M (or 50 .mu.M) test substance in 50 mM
potassium phosphate buffer for 5 min. The reaction is started with
NADPH. After 30 min 4 .mu.M midazolam (final concentration) are
added, and incubation is continued for 10 min. 75 .mu.l of the
reaction solution are removed after 10 min, and stopped with 150
.mu.l of acetonitrile solution.
Coincubation:
[0313] 0.05 mg/ml microsomal protein (human liver microsomes) are
preincubated with 4 .mu.M midazolam (final concentration) and 0-10
.mu.M (or 50 .mu.M) test substance in 50 mM potassium phosphate
buffer for 5 min. The reaction is started with NADPH. 75 .mu.l of
the reaction solution are removed after 10 min and stopped with 150
.mu.l of acetonitrile solution. The samples are frozen until the
MSMS analysis (modified from references: Obdach, Journal of
Pharmacology & Experimental Therapeutics, Vol 316, 1, 336-348,
2006; Walsky, Drug Metabolism and Disposition Vol 32, 6, 647-660,
2004).
8. Method for Determining the Solubility in Water (in Mg/Ml)
[0314] The solubility in water of the compounds of the invention
can be determined for example by the so-called shake flask method
(as specified in ASTM International: E 1148-02, Standard test
methods for measurement of aqueous solubility, Book of Standards
Volume 11.05.). This entails an excess of the solid compound being
put into a buffer solution with a particular pH (for example
phosphate buffer of pH 7.4), and the resulting mixture being shaken
or stirred until equilibrium has been set up (typically 24 or 48
hours, sometimes even up to 7 days). The undissolved solid is then
removed by filtration or centrifugation, and the concentration of
the dissolved compound is determined by UV spectroscopy or high
pressure liquid chromatography (HPLC) by means of an appropriate
calibration plot.
9. Results
[0315] The results of the receptor binding investigations are
expressed as receptor binding constants [K.sub.i(V1b),
K.sub.i(V1a), K.sub.i(V2), K.sub.i(OT)]. The results of the
investigation of the metabolic stability are indicated as
microsomal clearance (mCl).
[0316] The compounds of the invention show very high affinities for
the V1b receptor in these assays (maximally 100 nM, or maximally 50
nM, frequently <10 nM). The compounds also show high
selectivities vis-a-vis the V1a, V2 and/or OT receptor and a good
metabolic stability, measured as microsomal clearance.
[0317] The results are listed in table 3.
TABLE-US-00003 TABLE 3 Human microsomal K.sub.i(h-V1b)*
K.sub.i(h-V1a)/ K.sub.i(h-OT)/ clearance Example [nM]
K.sub.i(h-V1b)* K.sub.i(h-V1b)* [.mu.l min.sup.-1 mg.sup.-1] 1 +++
+++ +++ + 2 +++ +++ +++ + 2B +++ +++ +++ + 4 +++ +++ +++ +++ 4B +++
+++ +++ +++ 5 +++ +++ ++ + 10 +++ +++ +++ +++ 25 +++ +++ + ++ 28 ++
++ +++ +++ 32 ++ ++ +++ + 35 +++ ++ ++ + 37 +++ +++ +++ + 40 +++ ++
+++ ++ 55 +++ ++ + + K.sub.i(V1a)/ K.sub.i(OT)/ Human microsomal
Key: K.sub.i(V1b) K.sub.i(V1b) K.sub.i(V1b) clearance + >50-100
nM 15-25 15-25 >75-200 .mu.l min.sup.-1 mg.sup.-1 ++ 10-50 nM
>25-75 >25-45 50-75 .mu.l min.sup.-1 mg.sup.-1 +++ <10 nM
>75 >45 <50 .mu.l min.sup.-1 mg.sup.-1 *h = human
* * * * *